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Therefore do not worry about tomorrow,  
for tomorrow will worry about itself. 
Matthew 6:34 
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ABSTRACT 
Lyme borreliosis (LB) is a common tick-borne infectious disease in the Northern 
Hemisphere. The LB causing Borrelia burgdorferi sensu lato (Borrelia) spirochetes 
enter the human host via the tick bite. From the initial entry site Borrelia may 
disseminate in the blood vasculature to distant organs. In the disseminated stage of 
LB, the infection is manifested as inflammation in the joints, peripheral and central 
nervous system, skin or heart. LB patients are successfully treated with antibiotics. 
Without antibiotic treatment Borrelia adheres to the host molecules and is able to 
persist in the host tissues for a long time. 
The aims of this study were to investigate how Borrelia survives despite its 
limited metabolic capacity, how the host molecule biglycan affects the infectivity 
and dissemination of Borrelia in vivo, and, what was the LB seroprevalence in 
Finland fifty years ago, when LB was still an unrecognized disease. 
The study results showed that Borrelia expresses a periplasmic Basic membrane 
protein D involved in the salvage of purine nucleosides which are essential 
molecules for RNA and DNA synthesis. Further, the results revealed that biglycan 
affects the infectivity and dissemination of Borrelia in the mammalian host, and the 
host immune response. Finally, the results strongly suggested that LB was a common 
infectious disease in Finland half a century ago. 
In summary, the study results broaden the knowledge on the metabolism and 
pathogenesis of Borrelia, which is important for the discovery of novel vaccines or 
drug treatments. Further, knowledge on the LB seroprevalence fifty years ago helps 
to understand and proportionate the LB seroprevalence today. 
KEYWORDS: Lyme borreliosis, Borrelia burgdorferi, purine nucleoside, host 
molecule, biglycan, infectivity, immune response, seroprevalence 
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TIIVISTELMÄ 
Lymen borrelioosi on pohjoisella pallonpuoliskolla yleisin puutiaisvälitteinen 
infektiotauti. Borrelia burgdorferi sensu lato (borrelia) -spirokeettabakteerit 
pääsevät puutiaisen pureman kautta ihmisen ihoon ja leviävät verenkierrossa eri 
kudoksiin. Taudin levinneessä vaiheessa potilailla on usein tulehdusoireita nivelissä, 
ääreis- ja keskushermostossa, ihossa tai sydämessä. Borrelioosia voidaan hoitaa 
tehokkaasti antibiooteilla. Ilman antibioottihoitoa borreliabakteerit tarttuvat ihmisen 
omiin kudosmolekyyleihin sekä säilyvät kohdekudoksissa elinkykyisinä pitkään. 
Tämän tutkimuksen tavoitteina oli selvittää, miten borreliabakteerit selviävät 
pitkään elinkykyisenä suppeasta aineenvaihduntakyvystä huolimatta, miten 
biglykaani-kudosmolekyyli vaikuttaa bakteerin infektiokykyyn sekä selvittää, mikä 
oli borrelioosin yleisyys Suomessa vuosina 1968–72, jolloin borrelioosin 
taudinaiheuttajabakteeri oli vielä tuntematon. 
Tutkimustulokset osoittivat, että borreliabakteerit ottavat talteen elintärkeitä 
nukleosidejä RNA- ja DNA-synteesiä varten Basic membrane protein D (BmpD)  
-proteiinin avulla. Bakteerien sisäkalvolla sijaitseva BmpD-proteiini kuljettaa 
ainakin kahta eri puriininukleosidiä ihmisen kudosympäristöstä bakteerisolun 
sisälle. Toiseksi tutkimustulokset selvittivät, että biglykaani-kudosmolekyyli 
vaikuttaa borreliabakteerien infektiokykyyn ja leviämiseen sekä isäntäeläimen 
tulehdusvasteeseen. Lopuksi paljastettiin, että borrelioosi oli yleinen infektiotauti 
Suomessa 50 vuotta sitten. 
Yhteenvetona voidaan todeta, että tutkimustulokset tuovat uutta tietoa 
borreliabakteerin metaboliasta ja taudinaiheuttamiskyvystä, mitä voidaan hyödyntää 
tulevaisuudessa mm. rokote- ja lääkekehityksessä. Lisäksi tieto borrelioosin 
yleisyydestä vuosina 1968–72 auttaa suhteuttamaan borrelioosin yleisyyttä tänä 
päivänä. 
AVAINSANAT: Lymen borrelioosi, Borrelia burgdorferi, puriininukleosidi, 
kudosmolekyyli, biglykaani, infektiokyky, tulehdusvaste, seroprevalenssi  
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Abbreviations 
ABC ATP-binding cassette 
ACA acrodermatis chronica atrophicans 
AcGal 6‐O‐acylated cholesteryl β‐d‐galactopyranosides 
ADP adenosine diphosphate 
AMP adenosine monophosphate 
Amp ampicillin 
ATP adenosine triphosphate 
bgn biglycan 
Bmp Basic membrane protein 
bp base pair 
BSK-II Barbour-Stoenner-Kelly II  
C carboxyl group 
CCL C-C motif chemokine ligand 
cDNA complementary deoxyribonucleic acid 
CFSE carboxyfluorescein diacetate succinimidyl ester 
CI confidence intervals 
Cm chloramphenicol 
cp circular plasmid 
Cq quantification cycle 
CS chondroitin sulfate 
CSF cerebrospinal fluid 
CTP cytidine triphosphate 
CV column volume 
CXCL C-X-C motif chemokine ligand 
d deoxy 
DAPI 4′, 6-diamidino-2-phenylindole 
DAMP danger-associated molecular pattern 
Dbp  decorin-binding protein 
DNA deoxyribonucleic acid 
DS dermatan sulfate 
ECM extracellular matrix 
10 
EDTA ethylenediaminetetraacetic acid 
EIU enzyme immunoassay unit 
ELISA enzyme-linked immunosorbent assay 
EM erythema migrans 
FMC Finnish Mobile Clinic 
GAG glycosaminoglycan 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 
GMP guanosine monophosphate 
GTP guanosine triphosphate 
HRP horseradish peroxidase 
H2SO4 sulfuric acid 
HtrA serine protease high temperature requirement A 
Ig immunoglobulin 
IL interleukin 
IM inner membrane 
IMP inosine monophosphate 
kDa kilodalton 
Km kanamycin 
KO knock-out 
LA Lyme arthritis 
LB Lyme borreliosis 
LC-MS liquid chromatography-mass spectrometry 
LED light-emitting diode 
lp linear plasmid 
LPS lipopolysaccharide 
M molarity 
Mbp mega base pair 
MCP monocyte chemoattractant protein 
MIP macrophage inflammatory protein 
mRNA messenger RNA 
MST microscale thermophoresis 
MyD88 myeloid differentiation primary response 88 
n nano 
N amino group 
N nucleoside  
NaOH sodium hydroxide 
NF-κB nuclear factor kappa B 
Ni-NTA nickel-nitrilotriacetic acid 
NMP nucleoside monophosphate 
NSS normal sheep serum 
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OD optical density 
OM outer membrane 
OPD ortho-phenylenediamine 
Opp oligopeptide 
OR odds ratio 
Osp outer surface protein 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PG proteoglycan 
r recombinant protein 
RANTES regulated upon activation, normal T cell expressed and secreted 
rpm rounds per minute 
qPCR quantitative polymerase chain reaction 
RNA ribonucleic acid 
RT room temperature 
RT-qPCR reverse-transcriptase quantitative polymerase chain reaction 
SDS-PAGE sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
SEC size exclusion chromatography 
ss sensu stricto 
T Tween 20 
TCDM Turku Center for Disease Modeling 
TLR Toll-like receptor 
TNF tumor necrosis factor 
TTP thymidine triphosphate 
U enzyme unit 
USA United States of America 
UTP uridine triphosphate 
VlsE Vmp-like sequence 
VZV varicella zoster virus 
WCS whole-cell sonicate 
WT wildtype 
XMP xanthosine monophosphate 
 
  
12 
List of Original Publications 
This dissertation is based on the following original publications, which are referred 
to in the text by their Roman numerals: 
I Julia Cuellar, Mia Åstrand, Heli Elovaara, Annukka Pietikäinen, Saija Sirén, 
Arto Liljeblad, Gabriela Guédez, Tiina A. Salminen & Jukka Hytönen. 
Structural and biomolecular analyses of Borrelia burgdorferi BmpD reveal a 
substrate-binding protein of an ABC-type nucleoside transporter family. 
Accepted manuscript to Infection and Immunity. 
 
II Julia Cuellar, Annukka Pietikäinen, Otto Glader, Heidi Liljenbäck, Mirva 
Söderström, Saija Hurme, Jemiina Salo & Jukka Hytönen. Borrelia 
burgdorferi Infection in Biglycan Knockout Mice. The Journal of Infectious 
Diseases, 2019; 220, (1): 116–126. https://doi.org/10.1093/infdis/jiz050 
 
III Julia Cuellar, Timothée Dub, Jussi Sane & Jukka Hytönen. Seroprevalence of 
Lyme Borreliosis in Finland 50 years ago. Clinical Microbiology and 
Infection. In press. https://doi.org/10.1016/j.cmi.2019.10.003 
 
The original publications have been reproduced with the permission of the copyright 
holders. 
 
 13 
1 Introduction 
Lyme borreliosis (LB) is a tick-borne infectious disease common in Europe, Asia, 
and in North America. The LB causing spirochetes belong to the Borrelia 
burgdorferi sensu lato -complex (Borrelia) including about twenty different 
genospecies, where Borrelia burgdorferi sensu stricto, B. garinii, and B. afzelii are 
the most common human pathogens. Borrelia-infected Ixodes ticks transmit the 
spirochetes during feeding on a vertebrate host.  
Borrelia spirochetes are exceptional bacteria as they survive and maintain their 
infectivity in different host environments, such as in ticks, rodents, birds, and in 
humans. Borrelia is an auxotroph bacterium with a limited metabolic capacity. For 
example, Borrelia lacks the enzymes required for de novo synthesis of amino acids, 
fatty acids, cofactors, and nucleosides. Hence, the spirochetes express multiple 
transporter proteins for the uptake of nutrients from the host environment. Further, 
the outer surface of Borrelia is covered with proteins mediating adhesion to the host 
molecules enabling the dissemination and persistence of Borrelia in the host 
vasculature and extravascular tissues, such as in joints, nervous tissue, skin, and 
heart. The comprehensive characterization of Borrelia proteins, their function and 
interaction with host molecules (Studies I and II) is important for the development 
of vaccines and novel drugs supplementing the traditional antibiotics currently in 
use. 
LB was discovered forty years ago when first reports of tick bites, isolated 
Borrelia spirochetes, and subsequent arthritis reactions were published. Since the 
beginning of the 1990s, the LB seroprevalence among the healthy general population 
in various countries, regions, and in target groups with outdoor activities has been 
frequently studied. However, ticks and Borrelia have probably been circulating for 
thousands of years, and in order to elucidate LB occurrence in a longer retrospect, 
the seroprevalence of LB in Finland half a century ago was investigated (Study III). 
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2 Review of the Literature 
2.1 Lyme borreliosis 
2.1.1 History 
The bacterial agent, Borrelia burgdorferi sensu lato (later referred to “Borrelia”) and 
the resulting disease, Lyme borreliosis (LB), have been existing in the world 
probably for thousands of years as DNA of Borrelia was detected in the 5,300-year-
old Tyrolean iceman (Keller et al., 2012). Already in 1883, the German physician 
Alfred Buchwald described a chronic skin condition, acrodermatitis chronica 
atrophicans (ACA), which is today a well-known clinical manifestation of 
disseminated LB (Buchwald, 1883). In the beginning of the 20th century, the 
Swedish physician Arvid Afzelius described the occurrence of a red skin lesion after 
a tick bite (Afzelius, 1910). Also, two French neurologists, Charles Garin and 
Antoine Bujadoux, reported of patients with neurological symptoms after a tick bite 
(Garin & Bujadoux, 1922). In 1977, a new and previously unrecognized disease 
entity, “Lyme arthritis” (LA), was described for the first time. The rheumatologist 
Allen Steere and colleagues discovered an unusual high number of children suffering 
from arthritis in the communities of Lyme, Old Lyme, and East Haddam in 
Connecticut in the northeastern parts of the USA (Steere et al., 1977b). The 
investigators suggested that the infectious agent of LA was transmitted by an 
arthropod vector, possibly by a sheep tick (Steere et al., 1977b). 
Indeed, the ticks were found to be carriers of long and helical formed bacteria, 
the LA causing spirochetes. The spirochetes were successfully isolated and 
cultivated from ticks, Ixodes scapularis (formerly known as I. damminii) 
(Burgdorfer et al., 1982) and I. pacificus ticks in the USA (Burgdorfer et al., 1985), 
and I. ricinus ticks in Europe (Barbour, 1984; Burgdorfer, 1984). Also, antibodies in 
serum samples of LA patients bound the intact spirochetes isolated from the I. 
scapularis ticks (Burgdorfer et al., 1982). Later, the Borrelia spirochetes were 
isolated from blood, skin, and cerebrospinal fluid of Lyme disease patients (Benach 
et al., 1983; Steere et al., 1983). The name of the LA disease entity was broadened 
to Lyme disease in North America and to Lyme borreliosis in Europe as the 
multisystemic form of the infection was established (Steere et al., 1977a; Stanek et 
Review of the Literature 
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al., 1988; Stanek & Strle, 2018). Today, LB is known as the most common tick-
borne disease in the Northern Hemisphere (Stanek et al., 2012). 
2.1.2 Clinical manifestations 
LB is a multisystemic infection that is traditionally divided into three stages 1) early 
localized, 2) early disseminated, and 3) late disseminated stage (Steere, 2001; Stanek 
& Strle, 2018). 
In the early localized stage of LB, within days or weeks after the tick bite, a 
migrating skin lesion called erythema migrans (EM) occurs around the initial tick 
bite site in approximately 50–70% of European  (Berglund et al., 1995; Santino & 
Longobardi, 2011) and in 70–80% of North American LB cases (Steere & Sikand, 
2003). Additionally, the patient can experience flu-like symptoms, such as 
lymphadenopathy, fever, fatigue, joint, muscle pain, and malaise (Steere et al., 
2016). Also, lymphocytosis, a lymphocytic infiltration, may occur in the nipples of 
adults or in the ear lobes of children. After a few weeks, the EM can disappear even 
without antibiotic treatment (Steere et al., 1980). 
In the early disseminated stage, within weeks or months, the spirochetes have 
disseminated from the original entry site to other skin sites and distant organ sites, 
such as to the peripheral and/or central nervous system, or to the heart (Steere et al., 
2016). The clinical symptoms can be presented as multiple EMs in the skin, as 
objective signs of neuroborreliosis, or as acute cardiac symptoms due to disrupted 
electrophysiological conductance, or, in rare cases, as inflammation of the heart 
tissue. Neuroborreliosis is a subacute inflammatory condition often presenting with 
painful meningoradiculitis (Garin-Bujadoux-Bannwarth syndrome), lymphocytic 
meningitis, and cranial neuritis presented as uni- or bilateral facial palsy (Stanek et 
al., 2011; Borchers et al., 2015). 
In the late disseminated stage, usually months or years after the initial entry of 
the spirochetes, arthritis, and ACA might occur (Steere et al., 2016). Arthritis is 
presented as short, but recurrent attacks, or as long-lasting joint swelling and pain 
development affecting the large joints, such as knees (Stanek et al., 2011; Borchers 
et al., 2015). ACA is a persisting inflammatory skin condition starting with a bluish-
red discolouration of the extensor surfaces of lower or upper extremities (Stanek et 
al., 2011; Borchers et al., 2015). In time, the skin condition slowly progresses to skin 
atrophy (Stanek et al., 2011). 
The clinical symptoms of LB patients vary in different parts of the world as there 
are multiple Borrelia genospecies circulating (Stanek et al., 2012). For example, B. 
afzelii and B. garinii are mainly circulating in Europe. Thus, the persisting skin 
inflammation ACA and neuroborreliosis are often manifested in European patients 
(Ruzić-Sabljić et al., 2000; Strle et al., 2006). Whereas, B. burgdorferi sensu stricto 
Julia Cuellar 
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(ss) is the prevalent genospecies in North America. Hence, arthritis is a common 
symptom in North American patients (Steere & Sikand, 2003). 
2.1.3 Diagnosis and treatment of LB 
The diagnosis of EM is based on the clinical picture (Stanek et al., 2011). A red skin 
lesion qualifies as EM if the diameter is ≥5 cm (Borchers et al., 2015). Further, 
serological testing is not advised as only 50% of LB patients with EM have 
antibodies against Borrelia (Dessau et al., 2018).  
The diagnosis of early and late disseminated LB is performed by serology. The 
serological tests are feasible as the LB patients develop antibodies against Borrelia  
in approximately 4–6 weeks after a tick bite (Borchers et al., 2015). The Borrelia 
antibodies in serum or cerebrospinal fluid (CSF) are detected by enzyme-linked 
immunosorbent assays (ELISA) and by immunoblotting (Stanek et al., 2011; Dessau 
et al., 2018). Commonly, a two-step approach is used. At first, immunoglobulin (Ig) 
M and G are detected by a sensitive screening assay with whole-cell sonicate of 
Borrelia or recombinant antigens, such as VlsE or C6 peptide, a conserved region of 
the VlsE antigen (Mygland et al., 2010). In the second confirmatory test, an 
immunoblot with specific antigens of Borrelia is performed.  
Nowadays, Borrelia serological tests from different manufacturers vary in their 
antigenic composition and combination of recombinant proteins. For example, the 
first screening tests can contain whole-cell extracts of B. burgdorferi ss, B. afzelii, 
and/or B. garinii (Kodym et al., 2018). Also, the immunoblots are composed of a 
plethora of recombinant proteins, such as VlsE, flagellin, OspA, and OspC, derived 
from one  or various Borrelia genospecies (Kodym et al., 2018). Further, numerous 
other proteins of Borrelia have been investigated for their performance as antigens 
in serologic tests, such as BmpA, P66, and BBK32 (Aguero-Rosenfeld et al., 2005). 
Although laboratories use several commercial Borrelia antibody tests, especially the 
IgG test results are reliable. Recently, the Borrelia antibody assays used in twelve 
Scandinavian laboratories were compared (Lager et al., 2019). The study showed 
that the sensitivity of the diagnostic assays used in different laboratories was high 
(average 88%) as IgG results were similar in the investigated serum samples of LB 
patients and healthy control persons. 
The serologic tests are limited by the high background seroprevalence of the 
general population ranging from a few percent to over 20% in high risk groups 
(Mygland et al., 2010). As IgM and IgG towards Borrelia might persist for decades 
(Hammers-Berggren et al., 1993; Kalish et al., 2001), one cannot distinguish 
between acute and recurrent Borrelia infection by serologic tests (Steere et al., 2016). 
Hence, in cases of an atypical cutaneous manifestations or suspected LA, 
complementary laboratory tests for Borrelia detection can be performed (Stanek et 
Review of the Literature 
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al., 2011; Dessau et al., 2018). For example, a skin biopsy sample can be cultured in 
Barbour-Stoenner-Kelly II (BSK-II) medium. Further, Borrelia nucleic acid 
amplification test with polymerase chain reaction (PCR) can be performed on skin 
biopsy samples from the EM, synovial fluid, or CSF samples. 
The Borrelia infection is successfully treated with antibiotics of the class of β-
lactams (e.g. penicillin, amoxicillin, and ceftriaxone), tetracyclines (e.g. 
doxycycline), and macrolides (e.g. azithromycin) with treatment time up to four 
weeks (Borchers et al., 2015). According to Finnish Current Care Guidelines, 
doxycycline and amoxicillin are the first line of treatment in cases of EM and 
lymphocytoma (https://www.kaypahoito.fi/hoi13020#s14; accessed 9.12.2019). 
Further, patients with LA, neuroborreliosis, and ACA are intravenously treated with 
ceftriaxone (Oksi et al., 2008). Azithromycin is recommended as an alternative to 
doxycycline and penicillin if the LB patients are children, pregnant, breast-feeding, 
or have a drug allergy (Borchers et al., 2015).  
2.1.4 Vaccine development 
In 1998, the first LB vaccine, Lymerix by SmithKline Beecham (now GSK), was 
approved by the Federal Drug Administration in the USA (Schuijt et al., 2011). The 
immunogenic antigen was Outer surface protein A (OspA) of B. burgdorferi ss, a 
protein expressed only during the Borrelia colonization in the tick midgut. The 
bacterial transmission was blocked in the tick as anti-OspA antibodies transported 
via the blood meal contributed to the elimination of the spirochetes inside the midgut 
of the tick. Even though the mechanism-of-action was a brilliant idea, the immune 
response was short-lasting in humans, and several booster vaccine doses were 
necessary to maintain sufficient antibody response. Further, concerns of OspA 
vaccine-induced arthritis, due to suspected molecular mimicry, were raised (Embers 
& Narasimhan, 2013). Only after four years, the human OspA vaccine was 
withdrawn from the market. In 2014, a vaccination study conducted by the Baxter 
BioScience company showed that a multivalent vaccine containing OspA epitopes 
of four prevalent Borrelia genospecies, B. burgdorferi ss, B. afzelii, B. garinii, and 
B. bavariensis, was safe and immunogenic in healthy adults (Wressnigg et al., 2013; 
Wressnigg et al., 2014). However, the vaccination study was discontinued. 
Currently, the Austrian biotechnology company Valneva is conducting phase I 
clinical vaccination studies using an OspA-based fusion protein VLA15. In the 
preclinical studies, the mice immunized with VLA15 were protected from B. 
burgdorferi ss, B. afzelii, B. garinii, and B. bavariensis infection (Comstedt et al., 
2017). There are several commercial OspA vaccine on the market which are used in 
the veterinary field for vaccinating dogs (Schuijt et al., 2011) and as an “off-label” 
vaccine for horses (Divers et al., 2018).  
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The research for the development of a safe and effective LB vaccine is ongoing. 
In addition to the OspA protein, other Borrelia proteins and tick saliva proteins have 
been investigated as potential vaccine candidates (Table 1) either as single antigens 
or in cocktails of multiple antigens. For example, an immunization protocol with 
OspC in combination with OspA was studied (Grosenbaugh et al., 2018). However, 
the OspC/OspA fusion vaccine displayed lower immunogenicity compared to the 
monovalent OspA (Grosenbaugh et al., 2018). Also, an OspC cDNA tattoo vaccine, 
a novel vaccine technology, has been shown to prevent B. afzelii infection 
(Wagemakers et al., 2014). The plasmid expressing OspC was applied on the skin of 
mice, and was tattooed on the skin with a tattoo needle machine prior to the B. afzelii 
challenge (Wagemakers et al., 2014). The tattoo needle gun perforates the skin in 
thousands of spots, where the cDNA vaccine is deposited (Kim, 2017). The local 
skin trauma elicits a pro-inflammatory reaction, and thus, the DNA tattoo 
vaccination leads to a stronger and faster humoral and cellular immune response than 
traditional intramuscular vaccinations (Kim, 2017). Further, wildlife reservoir 
animals, mainly mice, have been vaccinated by oral bait vaccines containing vaccinia 
virus expressing OspA (Kern et al., 2016). Additionally, vaccinations of mice with 
live attenuated B. burgdorferi ss (Hahn et al., 2016), and different adjuvants boosting 
the OspA vaccine have been examined (Effenberg et al., 2017). 
Table 1. List of potential vaccine antigens, their function, and mechanism of action. The table is 
modified from (Schuijt et al., 2011) and (Singh et al., 2017). 
Vaccine antigen Function Mechanism of action Reference 
OspA Colonization of Borrelia in 
the tick midgut. 
Borrelia killed inside 
tick. 
(de Silva et al., 1996) 
(Pal et al., 2004) 
OspB Colonization of Borrelia in 
the tick midgut. 
Borrelia killed inside 
tick. 
(Neelakanta et al., 2007) 
(Fikrig et al., 2004) 
OspC Transmission of Borrelia 
from tick to mammalian 
host. 
Borrelia killed in mice. (Gilmore et al., 1996) 
DbpA Binding of Borrelia to host 
decorin. 
Protective after needle 
inoculation, not after 
tick infestation in mice. 
(Hanson et al., 1998) 
(Hagman et al., 2000) 
DbpB Binding of Borrelia to host 
decorin. 
Protective after needle 
inoculation in mice. 
(Hagman et al., 1998) 
BBK32 Binding of Borrelia to host 
fibronectin and mediating 
extravasation of Borrelia. 
Borrelia killed inside 
and outside tick. 
(Fikrig et al., 2000)  
(Moriarty et al., 2012) 
RevA Binding of Borrelia to host 
fibronectin. 
Borrelia killed after 
passive immunization 
in mice. 
(Floden et al., 2013) 
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Vaccine antigen Function Mechanism of action Reference 
AcGal Major glycolipid in cell 
membrane of Borrelia. 
Not determined. (Stübs et al., 2009) 
(Stübs et al., 2011) 
BBA65, BBA66, 
BBA69, BBA70, 
BBA73 
Borrelia proteins with 
unknown function. 
Not protective after 
tick infestation. 
(Brandt & Gilmore, 2017) 
BBI39 Borrelia protein expressed 
in ticks with unknown 
function. 
Borrelia killed inside 
tick. 
(Singh et al., 2017) 
BmpA, BmpB Borrelia proteins binding 
to purine nucleosides. 
Not protective after 
passive immunization 
in mice. 
(Pal et al., 2008) 
(Åstrand et al., 2019) 
BB0405 Borrelia protein with 
unknown function. 
Borrelia killed inside 
tick. 
(Kung et al., 2016) 
HtrA  Borrelia serine proteinase 
cleaving host proteins. 
Not protective after 
tick infestation. 
(Ullmann et al., 2015) 
Salp15 Tick protein.  Enhanced phagocytosis 
of Salp15 coated 
Borrelia in mice. 
(Dai et al., 2009) 
2.1.5 LB prevention and future treatment forms 
Currently, the prevention strategy of the tick-borne spirochete transmission is based 
on protective clothing, daily tick checks, and removal of the attached tick as early as 
possible. At the same time, it is important to bear in mind that removal of ticks within 
24–48 hours leads to no or very low risk of Borrelia infection in humans (Eisen, 
2018). In a recent study, the risk of developing LB after a tick bite in Scandinavia 
was estimated to be 2% (Wilhelmsson et al., 2016). 
In addition to novel LB vaccines, new treatment forms to combat LB infection have 
also been under investigation. Currently, Borrelia is susceptible to antimicrobial 
treatment as described above. However, worldwide, the antimicrobial resistance is an 
emerging health threat (López-Jácome et al., 2019). Hence, anti-adhesion based drugs 
have been envisioned to supplement the antibiotics currently in use (Ofek et al., 2003). 
For example, sugar side chains on host molecules are important binding targets for 
Borrelia (Lin et al., 2017). These interactions could be interfered by small molecules that 
either mimic or block directly the host binding components necessary for Borrelia 
adhesion (Lin et al., 2017). Further, the determination of the structure of Borrelia 
proteins can lead to the design of small molecules that interfere or inhibit protein 
function, and thus, the colonization and persistence of Borrelia in the host. For example, 
after solving the structure of a manganese transporter of Borrelia, small molecule drugs 
were discovered from existing drug libraries that inhibited the transporter function in 
Borrelia, and led to the rupture of Borrelia cells in vitro (Wagh et al., 2015).  
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2.1.6 Epidemiology 
2.1.6.1 Historical perspective 
The long-lasting Borrelia antibodies in human serum samples can be used in 
epidemiological studies, for example to investigate the seroprevalence of LB in a 
certain region or population group. The first LB seroprevalence studies using human 
serum samples were conducted in the late 1980s. 
Smith and colleagues were one of the first investigators, who studied the 
occupational risk of LB in outdoor workers compared to indoor workers by 
investigating Borrelia antibodies in sera of national park and office workers collected 
in 1986 (Smith et al., 1988). In all study participants, the total LB seroprevalence was 
6.5%. However, the investigators could only suggest that outdoor workers had higher 
risk of Borrelia infection as the number of indoor workers was too low for statistical 
analyses. During the same time period, the LB seroprevalence in Swiss orienteers was 
investigated in 1986 to 1987 (Zhioua et al., 1998). The orienteers presented high 
seroprevalence rates ranging from 28.1 to 30.3% compared to the control groups 
consisting of non-orienteers and healthy blood donors with seroprevalences of 3.9 to 
6.0%. The study results confirmed that outdoor activities in areas with high tick density 
led to high LB seroprevalence. Meanwhile in Mexico, the LB seroprevalence was 
studied using serum samples collected in 1987 to 1988 (Gordillo et al., 1999). The 
seroprevalence in Mexican population was determined as 0.3% indicating that LB is 
non-endemic in Mexico. 
The oldest serum samples investigated for Borrelia antibodies are collected from 
gray wolves in Minnesota and Wisconsin, USA, during the years 1972 to 1989 
(Thieking et al., 1992). The first Borrelia positive serum samples in the gray wolves 
were detected in the years 1975 to 1977 (Thieking et al., 1992), which is same time 
period when the first human LB patients were described (Steere et al., 1977b). In total, 
3% of the collected historical wolf serum samples contained Borrelia antibodies 
indicating that the gray wolves had been exposed to Borrelia infected ticks, and that 
wolves, similar to humans, are susceptible to LB (Thieking et al., 1992). 
Since the 1990s until today, the LB seroprevalences among healthy population in 
different regions (Table 2) and in various target groups have been well-characterized. 
However, no LB seroprevalence studies have been conducted in the decades pre-dating 
the early 1980s, when the LB disease entity was described for the first time. 
2.1.6.2 Present-day data 
At the present times, the LB epidemiological data in different geographical regions 
are obtained with diverse methodologies and from multiple sources (Sykes & 
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Makiello, 2017). In some countries, health authorities collect and release up-to-date 
surveillance data on LB cases in disease registries. However, there are differences 
whether only cases with disseminated LB or also cases with early localized LB are 
reported (Sajanti et al., 2017). Further, in some countries, the reporting is 
implemented only in certain regions within the country. For example in Germany, 
the reporting of LB cases is mandatory in 9 out of 16 federal states (Enkelmann et 
al., 2018). Commonly, the LB surveillance data is based on epidemiological studies. 
The LB epidemiological data are reported either as case numbers, as LB incidence 
rates (number of cases per 100,000 population) or as LB seroprevalence (proportion 
of population with serum antibodies towards Borrelia at a certain time point). 
The LB incidence rates and, thus, the LB seroprevalence in the general population, 
vary largely among European countries (Sykes & Makiello, 2017). In Western Europe, 
the unweighted mean incidence is estimated as 56 LB cases per 100,000 persons. This 
would equal to over 200,000 LB cases annually in Western European countries alone, 
where the total population is approximately 412 million. For comparison, the U.S. 
national health authorities estimated the LB incidence rate as 107 cases per 100,000 
persons. Hence, in the USA, there are approximately 329,000 LB cases annually with 
a total population of 312 million (https://www.census.gov/quickfacts/fact/table/ 
US/PST045218; accessed 21.5.2019).  
In summary, the LB seroprevalences in Europe are lowest in the Southern 
countries, intermediate in the Northern countries, and highest in Central and Eastern 
Europe (Table 2) (Sykes & Makiello, 2017). The lowest LB incidence rate with 0.001 
cases per 100,000 persons has been described in Italy, and the lowest LB 
seroprevalence among healthy population with 0.3% in Greece. In Central European 
countries (Belgium, France, Germany, The Netherlands, and Switzerland) the 
incidence rates range from 9 to 134 cases per 100,000 persons and the seroprevalences 
are approximately 1–10%. High seroprevalences of over 10% have been described in 
Eastern European countries (Poland and Slovakia). In Northern European countries 
(Denmark, Finland, Iceland, and Norway) the incidence rates fall to less than 31 cases 
per 100,000 persons, and the seroprevalences decrease to below 5%. Interestingly, 
Sweden is a country of high LB seroprevalence as in different regions the 
seroprevalence rates range from below 10% to over 20%. Also, one of the highest 
incidence rates of 464 LB cases per 100,000 persons in Europe has been described in 
an endemic region of Blekinge in Southeastern Sweden (Bennet et al., 2006).  
Another important fact in LB epidemiology is the considerably high LB 
seroprevalence in certain target groups. The LB seroprevalence is approximately 
20% in residents of LB endemic regions, such as in the Åland Islands (Carlsson et 
al., 1998), and in persons with occupational exposure to outdoors or with outdoor 
activities, such as forestry workers, hunters, farmers, and orienteers (Rath et al., 
Julia Cuellar 
22 
1996; Zhioua et al., 1998; Cinco et al., 2004; Johansson et al., 2017; Zajac et al., 
2017; De Keukeleire et al., 2018). 
Table 2.  List of LB seroprevalence in healthy population in selected European countries. 
 Country LB seroprevalence (%) Reference 
Low  
Greece 0.3 (Stamouli et al., 2000) 
Belgium 1.1–2.9 (De Keukeleire et al., 2017; 
Lernout et al., 2019) 
Italy 1.2–1.5 (Santino et al., 2004; Sonnleitner 
et al., 2015) 
Intermediate  
Finland (mainland) 3.9 (van Beek et al., 2018) 
Norway 2.5–4.4 (Vestrheim et al., 2016; Hvidsten 
et al., 2017) 
The Netherlands 5.0 (Kuiper et al., 1993) 
High 
Germany 4.0–9.4 (Dehnert et al., 2012;  
Wilking et al., 2015) 
Austria  7.2 (Sonnleitner et al., 2015) 
Sweden 8.0–22.0 (Tjernberg et al., 2007; 
Johansson et al., 2017) 
Serbia 8.6 (Jovanovic et al., 2015) 
Poland 12.5 (Chmielewska-Badora et al., 2012) 
Slovakia 12.8 (Bazovska et al., 2005) 
Spain 13.3 (Lledó et al., 2014) 
Åland Islands 19.5 (Carlsson et al., 1998) 
 
In Finland, there are approximately 2,000 cases with disseminated LB (Figure 1) and 
over 3,500 LB patients with EM based on clinical diagnosis each year (Sajanti et al., 
2017). Hence, the LB incidence rate was 120 cases per 100,000 population. The Åland 
Islands were excluded from the Finnish incidence rate calculation due to the fact of being 
an LB hyperendemic region with over 1,500 LB cases per 100,000 population. 
Importantly, the annual number of Finnish LB cases has been increasing since 1995 
when the notification of microbiologically confirmed LB cases by the Finnish National 
Institute of Health and Welfare authorities started (Figure 1). In 1995, there were only 
340 LB cases. In 2018, the number of LB cases had increased six-fold to more than 2,100 
notified cases. The highest number of over 2,300 cases was reported in the year 2017.  
In mainland Finland, the LB seroprevalence among healthy population was 3.9% 
in 2011(van Beek et al., 2018). The main risk factors associated with LB 
seroprevalence were male gender and age of 60 years and older (van Beek et al., 
2018). In contrast to mainland Finland, the LB seroprevalence in the Ålands Islands 
was 19.5% (Carlsson et al., 1998).  
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Figure 1.  The total number of disseminated LB cases in Finland including the Åland Islands during 
the years 1995 to 2019 as reported by the Finnish National Institute of Health and 
Welfare. The last update of the table was 25th November, 2019. (https://sampo.thl.fi/ 
pivot/prod/fi/ttr/shp/fact_shp?row=area-12260&column=time-12059&filter=reportgroup-
12465; accessed 4th December, 2019). 
2.2 Borrelia burgdorferi sensu lato 
2.2.1 Taxonomy 
The LB causing Borrelia spirochetes are classified in the kingdom of bacteria, in the 
phylum Spirochaetes, and in the order of Spirochetales (Norris et al., 2006). The order 
of Spirochetales includes three families, Brachyspiraceae, Leptospiraceae, and 
Spirochaetaceae. The family of Brachyspiraceae contains the bacteria of the genus 
Brachyspira. The Leptospiraceae family includes bacteria of the genera Leptonema 
and Leptospira. The Spirochaetaceae family consists of six genera, Borrelia, 
Brevinema, Cristispira, Spirochaeta, Spironema, and Treponema. The genus Borrelia 
includes the relapsing fever Borrelia and the LB Borrelia. Recently, the LB Borrelia 
has been proposed to be renamed as Borreliella (Adeolu & Gupta, 2014). The novel 
nomenclature is based on distinct phylogenetic and molecular markers between the 
relapsing fever and LB Borrelia species (Adeolu & Gupta, 2014). However, the 
proposed renaming has not been widely accepted in the Borrelia research community 
due to various reasons, such as confusion of the public and potential misdiagnosis of 
patients (Bergström & Normark, 2018; Stevenson et al., 2019). 
The LB causing Borrelia (or Borreliella), also known as the Borrelia burgdorferi 
sensu lato -complex, includes about twenty genospecies (Table 3) (Cutler et al., 
2017). The most important human LB pathogens are B. burgdorferi ss, B. afzelii, and 
B. garinii (Stanek & Reiter, 2011; Mead, 2015). B. valaisiana, B. spielmanii, B. 
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lusitaniae, B. bissettii, B. bavariensis, B. kurtenbachii, Candidatus B. andersonii, B. 
americana, and Ca. B. mayonii have been occasionally isolated from LB patients 
(Diza et al., 2004; Maraspin et al., 2006; de Carvalho et al., 2008; Rudenko et al., 
2008; Clark et al., 2014; Margos et al., 2014; Markowicz et al., 2015; Pritt et al., 
2016). Yet, the potential and importance of all these genospecies as human 
pathogens is not clearly established (Stanek et al., 2012). 
Table 3.  List of genospecies belonging to the Borrelia burgdorferi sensu lato -complex. Table is 
modified from (Yano et al., 1997; Masuzawa et al., 2001; Chu et al., 2008; Casjens et 
al., 2011; Hamer et al., 2012; Skuballa et al., 2012; Norte et al., 2013; Foley et al., 2014; 
Margos et al., 2014; Mead, 2015; Margos et al., 2016; Cutler et al., 2017; Johnson et 
al., 2017; Mysterud et al., 2019). 
Genospecies Human 
pathogen 
Competent host Geographical 
location 
B. afzelii Yes Mice, shrews, voles, squirrels, 
hares, badgers, hedgehogs 
Europe, Asia 
B. americana - Birds North America 
Ca. B. andersonii - Birds, rabbits North America 
B. bavariensis Yes Rodents, birds, hedgehogs Europe, Asia 
B. bissettii Possible Rats Europe, North 
America, Asia 
B. burgdorferi sensu stricto Yes Mice, birds, squirrels, foxes, 
hares 
Europe, North 
America 
B. californiensis - Rats North America 
B. carolinensis - Voles, mice North America 
B. chilensis - Unknown South America 
Ca. B. finlandensis - Unknown Europe 
B. garinii Yes Birds, squirrels, hares Europe, Asia 
B. japonica - Voles, mice Asia 
B. kurtenbachii - Rodents North America 
B. lusitaniae Possible Lizards, birds, mice Europe 
Ca. B. mayonii - Mice, squirrels North America 
B. sinica - Rodents Asia 
B. spielmanii Yes Hedgehogs Europe 
B. tanukii - Rodents, raccoon dogs Asia 
B. turdi - Birds Asia 
B. valaisiana Possible Birds, squirrels, badgers Europe 
B. yangtzensis - Rodents Asia 
Yes ~ Established human pathogens. Possible ~ Genospecies isolated from few patients. - ~ Not 
determined. 
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2.2.2 Cell biology 
Borrelia is a spirochete with a long thin spring-like morphology of 10−30 µm length 
and approximately 0.2 µm in diameter (Burgdorfer et al., 1982). The length of 
Borrelia varies among the genospecies. For example, the wildtype B. garinii SBK40 
and B. burgdorferi ss B31 are longer than laboratory strains, such as B. burgdorferi 
ss B313 and JF105 (personal observation). In Figure 2D, B. garinii SBK40 are 
adhering to the human brain microvascular endothelial cells. The length of B. garinii 
is estimated as 20 µm as the diameter of the cell nuclei is about 10 µm (Jiménez-
Munguía et al., 2018). 
 
Figure 2.  Borrelia adhering to endothelial cells. (A) The red actins and (B) blue nuclei of human 
brain microvascular endothelial cells stained with fluorescent anti-phalloidin and DAPI, 
respectively. (C) The green Borrelia stained with CFSE. (D) Merged image. All images 
magnified 200x. Photographs by Julia Cuellar. 
The didermic cell body of Borrelia includes an outer and inner membrane (Figure 
3). Using Gram staining, the resulting pink Borrelia is characterized as Gram-
negative bacteria. In contrast to the typical Gram-negative bacteria, such as 
Escherichia coli, the outer membrane of Borrelia is covered with lipoproteins 
instead of lipopolysaccharides (LPS) (Radolf et al., 2012). The outer surface 
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lipoproteins have diverse functions, such as adhesion to host tissues, mediating 
colonization, and evading from the host immune system (Caine & Coburn, 2016). 
Further, transporter proteins on the outer and inner membrane allow the uptake of 
nutrients from the host environment (Fraser et al., 1997). The Borrelia membranes 
consist mainly of lipids, phosphatidylcholine, phosphatidylglycerol, and cholesterol 
derivatives, such as 6-O-acylated cholesteryl β-d-galactopyranoside (AcGal) 
(LaRocca et al., 2010). Between the outer and inner membrane is the periplasmic 
space where the intracellular flagella are located (Figure 3) (Radolf et al., 2012). The 
flagella are important molecules for maintaining the coiled morphology and motility 
of Borrelia. A flagellum consists of multiple linear filaments attached to the both 
ends of Borrelia where intricate motor proteins fueled by chemiosmotic energy allow 
the rapid movement of Borrelia. 
 
Figure 3.  The schematic cell envelope of Borrelia shows the outer membrane (OM), inner 
membrane (IM), and the periplasmic space.The OM is covered with outer surface 
lipoproteins. The IM is composed of multiple membrane-spanning transporter proteins. 
Figure modified from (Radolf et al., 2012). DbpA ~ decorin-binding protein A, Opp ~ 
oligopeptide, OspA ~ outer surface protein A, PTS ~ phosphotransferase systems. 
The small, but fragmented and complex genome of Borrelia is unique among 
bacteria. The genome of B. burgdorferi ss B31 was the first Borrelia isolate to be 
completely sequenced (Fraser et al., 1997). Later, the complete genome of several 
isolates of B. burgdorferi ss, B. bissettii, B. spielmanii, B. valaisiana, B. garinii, and 
B. afzelii have been sequenced (Schutzer et al., 2011; Schutzer et al., 2012; Schüler 
et al., 2015; Jabbari et al., 2018). The complete or partial genomes of more than 30 
LB or relapsing fever Borrelia isolates have been deposited in the online database 
Review of the Literature 
 27 
BorreliaBase (Di et al., 2014). The Borrelia genome consists of one linear 
chromosome (approximately 1 Mbp) and of multiple linear and circular plasmids (in 
total approximately 0.6 Mbp) (Fraser et al., 1997). The linear chromosome contains 
housekeeping genes encoding for proteins involved in e.g. cellular processes, cell 
division and replication, and for multiple transporter proteins (Fraser et al., 1997; 
Casjens et al., 2012). The plasmids carry genes encoding virulence factors for 
infection and persistence in tick and mammalian hosts. Also, the plasmids can be 
easily lost during in vitro propagation of Borrelia. 
Although the number of linear and circular plasmids varies between genospecies 
(Casjens et al., 2012; Casjens et al., 2017), the core genome of Borrelia comprises 
the linear chromosome, the linear plasmid 54 (lp54), and the circular plasmid 26 
(cp26). The lp54 harbors genes encoding proteins essential for tick colonization 
(ospA), adhesion proteins (dbpAB), and pH- and temperature-regulated proteins 
(Maruskova et al., 2008). The cp26 carries genes essential for Borrelia survival, a 
telomere resolvase (resT), transporter proteins for peptides (oppA1-A5), glucose 
(bbb29), chitobiose (chbA-C), and purine bases (bbb22 and bbb23), enzymes 
involved in the purine salvage pathway (guaAB), and an important protein for tick-
to-host transmission (ospC) (Byram et al., 2004; Jewett et al., 2009; Jain et al., 2012). 
The limited metabolism is one additional striking feature of Borrelia (Fraser et 
al., 1997). Borrelia lacks the ability of de novo synthesis of amino acids, 
carbohydrates, fatty acids, enzyme cofactors, and nucleic acids. Hence, Borrelia 
needs to scavenge the nutrients from its host environment or from the nutrient-rich 
BSK-II medium. Borrelia expresses multiple transporters for amino acids, 
carbohydrates, anions, and cations (Fraser et al., 1997). Short peptides consisting of 
3 to 7 amino acids (proline and histidine in combination with leucine, valine or 
phenylalanine) are transported by the oligopeptide transporter system 
(OppABCDEF) (Lin et al., 2001; Wang et al., 2004; Groshong et al., 2017). The Opp 
transporter system is a typical bacterial ATP-binding transporter cassette (ABC) 
transporter (Figure 4) (Maqbool et al., 2015) as it comprises five substrate-binding 
proteins for oligopeptides (OppA1-A5), two heterodimeric permeases (OppB1C1), 
and a heterodimeric nucleotide-binding domain (OppEF) (Groshong et al., 2017). 
Also, carbohydrates (glucose, mannose, maltose, chitobiose, glycerol, N-
acetylglucosamine) are transported via specific transporters (von Lackum et al., 
2005; Rhodes et al., 2010; Corona & Schwartz, 2015). Accordingly, transporter 
proteins for anions and cofactors, such as phosphate (Brautigam et al., 2014), 
riboflavin (Deka et al., 2013), and manganese (Ouyang et al., 2009) have been 
described. 
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In contrast, no genes encoding for fatty acid or nucleic acid transporters were 
identified by genomic sequencing in 1997 (Fraser et al., 1997). The uptake of fatty 
acids by passive diffusion might circumvent the need for a specific transporter as the 
outer membrane is relatively permeable due to lack of LPS (Cox & Radolf, 2001). 
On the other hand, in a recent study, members of the Basic membrane protein (Bmp) 
family, BmpA, BmpB, BmpC and BmpD, were predicted as components of the ABC 
transporter for purine nucleosides in Borrelia (Åstrand et al., 2019). The BmpA-D 
are encoded in the chromosome (bb0383, bb0382, bb0384, bb0385, respectively) 
suggesting that Bmps are important housekeeping proteins for Borrelia survival 
(Ramamoorthy et al., 1996; Bryksin et al., 2005). The first known bacterial purine 
nucleoside transporter was discovered in the Treponema pallidum spirochete and 
named as purine nucleoside receptor A (PnrA) (Deka et al., 2006). At the amino acid 
sequence level, the Bmps of Borrelia are related to T. pallidum PnrA with amino 
acid sequence identities of 27.5 to 31.3% (Åstrand et al., 2019). Strikingly, the 3D 
modeling structure of Bmps in silico suggest their function to be substrate-binding 
proteins possibly preferring purine nucleoside as ligands. However, the in silico 
structure predictions need to be confirmed with protein crystallization. 
2.2.3 Purine and pyrimidine salvage 
As described above, Borrelia lacks the ability to synthesize nucleic acids and its 
derivatives de novo. Hence, Borrelia depends on purine and pyrimidine salvage from 
extracellular sources. The nucleotides, nucleosides, purine and pyrimidine bases 
(Figure 5) are available in the tick midgut and saliva after a blood meal, and in the 
Figure 4. Schematic presentation of a 
bacterial ATP-binding cassette (ABC) 
transporter system for nutrient uptake. 
Nutrients (black triangles) enter the 
periplasmic space via porins located in the 
outer membrane (OM). Substrate-binding 
protein (SBP) anchored to the inner 
membrane (IM) transport the nutrient to 
permeases (P) which import the nutrients into 
the bacterial cell. The nucleotide-binding 
domains (NBD) drive the nutrient transport by 
hydrolyzing ATP to ADP. Modified from 
(Groshong et al., 2017). 
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host tissues at the infection sites due to cell lysis and nucleic acid degradation by the 
host innate immunity (Lawrence et al., 2009). 
 
Figure 5.  The purine (grey boxes) and pyrimidine bases (blue boxes), nucleosides and 
nucleotides essential for Borrelia. The nucleosides are either ribosylated (left green box) 
or deoxyribosylated (right green box). The abbreviations marked in the parentheses are 
used in Figures 6 and 7. 
The complex Borrelia salvage pathway for purine and pyrimidine bases and 
nucleosides is depicted in Figure 6 and 7, respectively. First, the nucleotides, 
nucleosides, and their deoxygenated forms, deoxynucleotides and deoxynu-
cleosides, and the free purine and pyrimidine bases traverse the outer membrane of 
Borrelia, possibly through porins allowing the diffusion of small hydrophilic 
molecules (Bárcena-Uribarri et al., 2010). In the periplasmic space, the nucleotides 
are dephosphorylated by nucleotidases to nucleosides. For example, the AMP 
nucleotide, is converted by a putative nucleotidase BB0504 to adenosine, its 
nucleoside form (Lawrence et al., 2009). Then, adenosine and other nucleosides are 
imported by a putative nucleoside ABC transporter (BB0677–79) into the cytoplasm 
(Lawrence et al., 2009; Gherardini et al., 2010; Corona & Schwartz, 2015).  
In contrast to the purine nucleotides, the purine bases can freely enter the bacterial 
cytoplasm via specific transporters for purine bases (Figure 6). Adenine, 
hypoxanthine, and guanine are imported inside the bacterial cytoplasm by two 
characterized Borrelia purine transporters encoded by the bb222 and bb223 in the cp26 
(Byram et al., 2004; Jain et al., 2012). Although individual BB222 and BB223 have 
different affinities towards hypoxanthine, adenine, and guanine, both transporters are 
required for maintaining the infectivity of Borrelia in the mammalian host, but not for 
in vitro growth as BSK-II medium is rich of nutrients containing nucleotides, 
nucleosides, and free bases (Jain et al., 2012; Jain et al., 2015). 
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The purine base hypoxanthine plays a central role in the purine salvage pathway 
(Figure 6). Hypoxanthine is either directly imported from the host environment (Jain 
et al., 2012) or adenine is deaminated by adenine deaminase to hypoxanthine (Jewett 
et al., 2007; Lawrence et al., 2009; Jain et al., 2015). For DNA synthesis, 
hypoxanthine is first converted to deoxyinosine by deoxyribosyl transferase, and 
then, is phosphorylated to deoxyinosine monophosophate (dIMP) by a 
deoxynucleotide kinase (Lawrence et al., 2009; Gherardini et al., 2010). 
Alternatively, for RNA synthesis, hypoxanthine is directly converted to IMP by 
xanthine-guanine phosphoribosyl transferase. The final enzymatic steps before DNA 
and RNA synthesis are similar. The (d)IMP is converted by IMP dehydrogenase to 
(d)XMP, and by GMP synthase to (d)GMP (Jewett et al., 2009). Two phosphate 
groups are added to the (d)GMP by a nucleoside di-phosphate kinase (BB0463) to 
gain (d)GTP before incorporating dGTP for DNA and GTP for RNA synthesis 
(Lawrence et al., 2009; Gherardini et al., 2010). 
 
Figure 6.  Putative purine salvage pathway of Borrelia. The free purine bases, adenine (Ade), 
guanine (Gua), xanthine (Xan), hypoxantine (Hyp), or any nucleoside monophosphate 
(NMP) are traversing the outer membrane (OM) of the bacterial cell possibly through 
porins. The NMPs are dephosphorylated to nucleosides by a nucleotidase, such as 
BB0504. The free bases are imported by known transporters expressed on the inner 
membrane (IM), such as BBB22 and BBB23, and the nucleosides by presumed 
transporters (dashed ellipses), such as BB677−79, or by unknown transporters (empty 
dashed ellipses). The bases or nucleosides are enzymatically converted to 
ribonucleotides or deoxyribonucleotides for RNA and DNA synthesis. The enzymes are 
listed in Table 4. The dashed arrows indicate unknown enzymes. Modified from 
(Gherardini et al., 2010). 
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Only two pyrimidine nucleosides, cytidine and deoxycytidine are rescued (Figure 7) 
(Zhong et al., 2006; Lawrence et al., 2009; Gherardini et al., 2010). Cytidine is the 
precursor for two RNA pyrimidine bases, cytidine triphosphate (CTP), and uridine 
triphosphate (UTP). Deoxycytidine is the precursor for deoxycytidine triphosphate 
(dCTP) and deoxythymidine triphosphate (dTTP) for DNA incorporation.  
 
Figure 7.  Putative pyrimidine salvage pathway of Borrelia. The free pyrimidine bases, cytidine 
(Cyd) and deoxycytidine (dCyd), are traversing the outer membrane (OM) of the 
bacterial cell, possibly by porins. The free bases are imported by unknown transporters 
(empty dashed ellipses). The bases are enzymatically converted to ribonucleotides or 
deoxyribonucleotides for RNA and DNA synthesis. The enzymes are listed in Table 4. 
Modified from (Gherardini et al., 2010). 
The enzymes involved in the Borrelia purine and pyrimidine salvage pathway are 
listed in Table 4. Borrelia lacks three enzymes of the classical purine salvage 
pathway that are encoded by the relapsing fever strains, Borrelia hermsii and 
Borrelia turicatae (Pettersson et al., 2007). First, the ribonucleotide reductase 
catalyzing the conversion of ribosylated nucleotides to their deoxyribosylated form 
is not present in Borrelia. Also, the adenylosuccinate synthase and lyase catalyzing 
the formation of IMP to AMP are lacking. Hence, Borrelia is not able to convert 
ribosylated purines (ATP and GTP) to deoxyribosylated forms (dATP and dGTP). 
Further, the scavenging of adenine is essential as the conversion of IMP to AMP is 
not feasible. 
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Table 4.  Existing and absent enzymes involved in the classical purine and pyrimidine salvage 
pathway of Borrelia. Modified from (Pettersson et al., 2007; Gherardini et al., 2010). 
Enzyme name Gene 
designation 
Open reading frame 
in Borrelia 
Adenine deaminase adeC bbk17 
Adenine phosphoribosyltransferase apt bb0777 
Adenylate kinase adk bb0417 
Deoxynucleoside kinase dgk bb0239 
Deoxyribosyl transferase ptd bb0426 
GMP synthase guaA bbb18 
IMP dehydrogenase guaB bbb17 
Guanine-hypoxanthine permease pbuG bbb22, bbb23 
Nucleoside diphosphate kinase ndk bb0463 
Nucleotidase - bb0504 
Xanthine-guanine phosphoribosyltransferase gpt bb0103 
Cytidine deaminase cda bb0618 
Thymidine kinase tdk bb0793 
CTP synthase pyrG bb0575 
Uridylate kinase pyrH bb0571 
Uridine kinase udk bb0015 
Cytidylate kinase  cmk bb0819, bb0128 
Thymidylate synthase thyX bba76 
Hypoxanthine-guanine phosphoribosyltransferase hpt - 
Adenylosuccinate synthase purA - 
Adenylosuccinate lyase purB - 
Auxiliary (NrdI) protein nrdI - 
Ribonucleotide-diphosphate reductase alpha 
subunit 
nrdE - 
Ribonucleotide-diphosphate reductase beta 
subunit 
nrdF - 
2.3 Pathogen-host interaction 
2.3.1 The tick vector 
Borrelia is a zoonotic bacterium that naturally circulates between its arthropod 
vector, the Ixodes ticks (Figure 8), and the competent reservoir animals (rodents, 
squirrels, birds) and the incompetent large animals (deer) (Mysterud et al., 2019). 
The host animals are classified as (in)competent depending on their (un)ability to 
become infected with Borrelia and to be a source of infection for their vector 
(Mysterud et al., 2019). 
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In general, ticks are ectoparasites temporarily living on vertebrate hosts for blood 
meal acquisition, and can transmit multiple infectious agents, such as bacteria, 
viruses, and parasites (Estrada-Peña & de la Fuente, 2014; Boulanger et al., 2019). 
There are 900 identified tick species which are mainly divided into two families: 
hard ticks (Ixodidae) and soft ticks (Argasidae) (Boulanger et al., 2019). For 
example, the relapsing fever Borrelia are transmitted by soft ticks, Ornithodoros and 
Argas ticks, except for B. recurrentis and B. miyamotoi which are transmitted by 
body lice and I. ricinus ticks, respectively. Examples of the hard ticks, I. ricinus and 
I. persulcatus, transmit, in addition to Borrelia, the tick-borne encephalitis (TBE) 
virus. Another hard tick, Hyalomma marginatum prevalent in warm climate 
countries, carries the Crimean-Congo hemorrhagic fever virus.  
 
Figure 8.  The life cycle of an Ixodes tick starts with the larva hatching from the eggs. The larva 
molts to a nymph and later to an adult. Between each developmental stage, the tick 
acquires a blood meal from host animals. The tick becomes infected if it feeds on an 
infected host. The tick can transmit the infectious agent to the following host animal. 
Humans are accidental hosts. From the intial tick bite site, Borrelia (green) can 
disseminate and cause inflammation in the joints, nervous system, heart, or skin. Figure 
modified from (Radolf et al., 2012). 
There are four species of Ixodes ticks transmitting Borrelia infection. I. ricinus and 
I. persulcatus are the prevalent ticks in Europe and I. persulcatus in Asia (Radolf et 
al., 2012; Estrada-Peña et al., 2018). In Finland, both I. ricinus and I. persulcatus 
exist due to its proximity to the Eurasian border (Laaksonen et al., 2017). 16.9% and 
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1.6% of the ticks in Finland are infected with Borrelia and TBE virus, respectively. 
I. scapularis and I. pacificus are the main ticks in eastern and western North 
America, respectively (Radolf et al., 2012; Dumic & Severnini, 2018). Factors such 
as climate change, milder winters, faster developmental rates of ticks, and increasing 
host density lead to the spread of ticks towards northern latitudes and higher altitudes 
(Laaksonen et al., 2017; Estrada-Peña et al., 2018). 
The length of a tick life cycle varies from one to four years depending on the 
climate (Estrada-Peña & de la Fuente, 2014). In cold climate regions, the life cycle 
of a tick is longer. In countries with continental climate, ticks are active from March 
to October, whereas in oceanic countries, ticks can be active all year round 
(Boulanger et al., 2019). In Finland, I. ricinus is active from April to November and 
I. persulcatus from April to July with high seasonal activity peak in the early summer 
months (Laaksonen et al., 2017).  
The life cycle of ticks involves four stages: egg, larva, nymph, and female or 
male adult (Figure 8) (Estrada-Peña & de la Fuente, 2014; Boulanger et al., 2019). 
The larval tick hatches from the eggs laid by a female tick. The newly hatched larva 
acquires its first blood meal from a small vertebrate animal, such as a rodent, squirrel 
or a bird. After feeding, the larva drops to the ground and molts to a nymph. During 
the nymphal stage, the tick acquires its second blood meal before molting to an adult. 
The resulting adult tick feeds on a third host, such as a deer, then mates, and the 
female tick lays thousands of eggs on the ground. If the tick feeds on an infected host 
animal, the tick will become infected with Borrelia. In Europe, mainly rodents and 
migratory birds are infected with B. afzelii and B. garinii, respectively, and mice are 
infected with B. burgdorferi ss in North America (Table 3) (Radolf et al., 2012).  
Notably, the transmission of Borrelia in ticks is transstadial as the female adult 
cannot pass on the infection to its offspring (Estrada-Peña & de la Fuente, 2014). In 
contrast, the transmission of the relapsing fever B. miyamotoi is transovarial (Richter 
et al., 2012; van Duijvendijk et al., 2016). Hence, larvae may be infected with B. 
miyamotoi and can transmit the spirochetes to their first host animal. In rare cases 
Borrelia infected larvae are also detected (Richter et al., 2012; van Duijvendijk et al., 
2016).  Most likely, the acquisition of the Borrelia occurred during feeding on the host, 
but the feeding was interrupted, and larvae could not molt to the nymphal stage. 
2.3.2 Infection of the host 
Humans and companion animals, such as dogs and cats, are accidental hosts of the 
ticks (Radolf et al., 2012; Estrada-Peña & de la Fuente, 2014; Boulanger et al., 2019). 
During outdoor activities humans and companion animals visit forests and fields, the 
typical habitats of ticks, and may encounter a questing tick. A questing tick sitting 
on the tip of grasses or leaves detects a passing animal or human with its complex 
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sensory system (sensory bristles, pedipalps, and Haller's organ on front legs) and 
attaches to the skin of the host. Once on the skin, the tick locates a warm and humid 
spot, perforates the skin with its feeding mouth parts, and releases a cement-like 
substance securing the attachment of the tick to the skin. After a few hours, the tick 
starts to insert saliva into the feeding cavity. The tick saliva is abundant of 
pharmacologically active compounds inducing cells lysis around the feeding cavity, 
enabling blood flow into the feeding cavity, and evading the host inflammatory 
response (Šimo et al., 2017). Often the tick bite is not noticed as pain is inhibited by 
bradykininases cleaving bradykinin, the pain and inflammation signaling molecule 
in humans (Šimo et al., 2017). 
The warm blood meal entering the tick midgut is the escape signal for Borrelia. 
The Borrelia residing in the unfed tick midgut are firmly attached as OspA expressed 
on the Borrelia binds to the tick receptor for OspA (TROSPA) expressed on the 
surface of the tick midgut (Pal et al., 2004). After the blood arrives in the tick midgut, 
the OspA expression on Borrelia is downregulated and the OspC is upregulated 
which is an important protein for establishing Borrelia infection in the vertebrate 
host (Schwan & Piesman, 2000). The arriving blood contains serum proteins of the 
complement system of the vertebrate host innate immune system. Thus, Borrelia 
also expresses complement regulator-binding proteins to survive the complement-
mediated killing (Hart et al., 2018). Borrelia released from the tick midgut, spreads 
first to the tick salivary glands via the haemocoel, and then enters the host skin via 
the tick saliva (Schwan & Piesman, 2000). As shown by experimental transmission, 
after 12 hours of tick attachment, Borrelia is transmitted from the nymphal ticks and 
after 24 hours from adult ticks to mice (Sertour et al., 2018). 
2.3.3 Host immune response 
During the early phase of infection, the activated host complement system continues 
to fight the entering Borrelia (Kraiczy, 2016). Further, Borrelia is recognized by the 
innate immune cells residing in the skin of the host (Radolf et al., 2012). The first 
arriving innate immune cells are the neutrophils, which recognize and kill effectively 
the invading Borrelia (Steere et al., 2016). Within 24 hours, the neutrophils disappear, 
but other innate immune cells, such as dendritic cells, monocytes and macrophages, 
and adaptive immune cells, such as T cells, remain (Steere et al., 2016). Borrelia is 
detected by pattern-recognition receptors which are expressed on the host innate 
immune cells and non-immune cells (epithelial cells, endothelial cells, and fibroblasts) 
for recognition and phagocytosis of microbes or pathogenic host cell particles 
(Takeuchi & Akira, 2010). The family of Toll-like receptors (TLRs) represents the 
major pattern-recognition receptors in Borrelia infection (Steere et al., 2016). In 
general, the TLRs detect bacteria, viruses, and protozoa by pathogen-associated 
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molecular patterns, such as flagella, di- or triacylated lipoproteins and single- or double 
stranded DNA and RNA (Takeuchi & Akira, 2010). 
The host immune response against Borrelia infection via TLR2 is the best 
characterized signaling pathway, although TLR5, TLR7, TLR8, and TLR9 and other 
signaling pathways are also involved (Wooten et al., 2002; Shin et al., 2008; 
Petnicki-Ocwieja & Kern, 2014; Petzke & Schwartz, 2015). The TLR2 forms a 
heterodimer with TLR1 on the surface of innate immune cells, and recognizes the 
tripalmitoyl-S-glycerylcysteine lipid modified Borrelia outer surface proteins 
(Hirschfeld et al., 1999; Wooten et al., 2002). The binding of TLR2 to Borrelia leads 
to the cellular downstream effect of translocation of the nuclear factor κB (NF-κB) 
via the myeloid differentiation primary response gene 88 (MyD88) -dependent 
signaling pathway (Petnicki-Ocwieja & Kern, 2014; Petzke & Schwartz, 2015). The 
NF-κB activates the expression of proinflammatory cytokines, such as interleukin 
(IL) 1β, IL-6, IL-8, IL-12, tumor necrosis factor (TNF) α, type 1 interferon,  and 
adhesion factors, such as E-selectin, vascular cell adhesion molecule 1, and 
intracellular adhesion molecule 1 (Shin et al., 2008; Cervantes et al., 2011; Petnicki-
Ocwieja & Kern, 2014; Petzke & Schwartz, 2015). Further, TLR2 signaling induces 
the internalization and phagocytosis of Borrelia in the phagosomes of monocytes 
(Cervantes et al., 2011). The pivotal roles of TLR2 and MyD88 in the phagocytosis 
of Borrelia are evident from the infection studies using TLR2- or MyD88-deficient 
mice (Wooten et al., 2002; Bolz et al., 2004). Mice lacking TLR2 or MyD88 were 
unable to control spirochetemia as the amount of Borrelia genomes in the investi-
gated tissues were significantly higher in TLR2- and MyD88-deficient mice than in 
the tissues of wildtype mice. Notably, TLR2- or MyD88-deficiency did not reduce 
production of antibodies. 
During the disseminated phase of Borrelia infection, the adaptive immunity is 
crucial for clearing of bacteria and for controlling the inflammatory response (Radolf 
et al., 2012). Despite the short blood-borne phase during dissemination, Borrelia 
releases antigens which are eventually passing through the spleen (Belperron et al., 
2007).  In the spleen, the marginal zone B cells (MZB) detect the Borrelia-specific 
antigens and recognize those as foreign antigens, and subsequently, the MZBs start 
producing IgM antibodies targeting Borrelia. Later, the B cells with the help of the 
T cells start producing Borrelia-specific IgG antibodies which are detected earlierst 
after two weeks of infection by serologic tests (Tunev et al., 2011; Steere et al., 2016; 
Tracy & Baumgarth, 2017). IgG antibodies towards Borrelia are produced in 99% 
of patients (Dessau et al., 2018), and the IgGs remain elevated for more than ten to 
twenty years and probably longer (Kalish et al., 2001). 
Interestingly, the combined effect of the innate and adaptive immunity is able to 
clear Borrelia infection within several months or years (Steere et al., 2016). Even 
Review of the Literature 
 37 
the clinical symptoms resolve eventually without antibiotic treatment (Steere et al., 
1987), except for the persisting ACA skin inflammation (Steere et al., 2016). 
2.3.4 Dissemination and persistence of Borrelia in the human 
host tissues 
Despite the host innate immune response during the early phase of infection, 
Borrelia establishes infection using multiple immune evasion strategies. First, the 
expression of OspC on the outer surface of Borrelia is required for mammalian 
infection (Grimm et al., 2004). OspC binds to tick protein Salp15 leading to the 
evasion from the complement-mediated killing (Schuijt et al., 2008).  Further, OspC 
protects Borrelia from phagocytosis by the host macrophages (Carrasco et al., 2015). 
At the same time, the highly expressed OspC has its disadvantage as it is easily 
recognized by host immune cells leading to the production of antibodies (Magnarelli 
et al., 1996). Hence, within two to three weeks, the OspC expression in Borrelia is 
downregulated (Liang et al., 2002; Liang et al., 2004), and the significance of 
multiple other virulence factors, such as the antigenic variation protein VlsE (Vmp-
like sequence E), becomes more prominent (Liang et al., 2004; Radolf et al., 2012). 
Borrelia starts to disseminate from the initial tick bite site within two days (Shih 
et al., 1992). As described above, Borrelia is motile and can spread between the cells 
in the extracellular matrix (ECM) consisting of macromolecules surrounding all 
types of organs and tissues (Radolf et al., 2012). To facilitate its movement in the 
ECM and to enter the blood vasculature by piercing the blood vessels walls, Borrelia 
activates the host matrix metalloproteases, and the host fibrinolytic system including 
plasminogen, and its activator, urokinase, to degrade the ECM macromolecules 
(Grab et al., 2005; Behera et al., 2006). 
Borrelia disseminates to distant organ sites via the blood vessels and probably via 
the lymphatic vessels (Radolf et al., 2012; Tracy & Baumgarth, 2017). In the 
bloodstream, Borrelia evades the complement-mediated killing by binding to Factor H 
and Factor H -like protein 1 with its surface-exposed complement regulator-acquiring 
surface proteins (CRASPs) (Mühleip et al., 2018). The extravasation of Borrelia to the 
surrounding target tissue, is mediated by the vascular-adhesion protein BBK32 
(Moriarty et al., 2012). BBK32 binds to glycosaminoglycans (GAGs) and fibronectin 
on the vascular surface resulting in slowing down of the movement of Borrelia and in 
tethering and dragging interactions of Borrelia with the vascular endothelium before 
entering the extravascular tissue (Moriarty et al., 2012; Ebady et al., 2016).  
In the extravascular tissues, such as in the joints, peripheral and central nervous 
system, skin or in the heart, Borrelia is able to persist for a long time as it adheres to 
multiple ECM macromolecules, such as to fibronectin, laminin, proteoglycans and 
to GAGs (Caine & Coburn, 2016). For example, the Borrelia outer surface protein 
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RevA binds to fibronectin (Brissette et al., 2009a), Erpx and BmpA bind to laminin 
(Brissette et al., 2009b; Verma et al., 2009) and DbpA and B are known to bind to 
two proteoglycans, biglycan and decorin (Guo et al., 1995; Guo et al., 1998; Salo et 
al., 2011; Salo et al., 2016). Importantly, the adhesion proteins of Borrelia display 
redundancy and multifunctionality (Caine & Coburn, 2016). 
2.3.5 Biglycan and decorin 
The ECM consisting of multiple macromolecules (collagens, elastins, fibronectin, 
laminins, glycoproteins, proteoglycans and gylcosaminoglycans) provides a physical 
scaffold for the cells in organs and tissues, but also regulates multiple cellular 
functions (Theocharis et al., 2016). The proteoglycans (PGs) are the largest family 
of ECM macromolecules with diverse structures and functions. The PGs are 
composed of a core protein and of one or several attached GAG chains. The GAGs 
are linear polysaccharides consisting of repeating di-saccharides of an amino sugar 
and uronic acid or galactose. The GAGs can be classified as chondroitin sulfate (CS), 
dermatan sulfate (DS) and to heparan sulfate, heparin, keratan sulfate and hyaluronan 
glucosaminoglycans. 
Biglycan and decorin are PGs belonging to the class I of the small leucine-rich 
proteoglycans that are expressed overall in the ECM. Biglycan has a core protein of 
42 kDa with two attached GAG chains (Figure 9) (Fisher et al., 1989; Bianco et al., 
1990). The core protein of decorin is approximately 45 kDa with one attached GAG 
chain (Fisher et al., 1989; Theocharis et al., 2016). The GAG chains are either DS or 
CS depending on the tissue site. Biglycan has two and decorin has three attachment 
sites for N-linked oligosaccharides possibly preventing the self-aggregation of the 
PG (Iozzo, 1998). 
 
Figure 9.  Schematic structure of biglycan. The biglycan core protein contains four domains (I–IV). 
Domain I consists of a signal peptide and a pro-peptide that are cleaved before secretion 
into the extracellular matrix. Domain II consists of four cysteines and the attachment 
sites for two glycosaminoglycan (GAG) side chains. Domain III consists of the leucine-
rich tandem repeats and the attachment sites for two N-linked oligosaccharides. Domain 
IV consists of two cysteines. Modified from (Iozzo, 1998; Sainio & Järveläinen, 2019). 
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The name decorin derives from the function of the core protein as it “decorates” 
collagen bundles (Theocharis et al., 2016). Hence, decorin is found in the ECM of 
collagen-rich connective tissues, such as in skin, joints, tendons, in the connective 
sheaths of skeletal muscles, in peripheral nerves and in the eye cornea (Bianco et al., 
1990). Notably, decorin deficiency leads to a fragile skin phenotype (Corsi et al., 
2002). Biglycan is also expressed in the ECM of connective tissues, but in 
specialized cell types. For example, both decorin and biglycan are expressed in the 
skin (Bianco et al., 1990). Decorin is found in the dermal matrix of the skin, whereas, 
biglycan is expressed in the keratinocytes of the epidermis and in the endothelial 
cells of dermal capillaries. Although both PGs are expressed in the cartilage and 
bones, only biglycan deficiency leads to decreased skeletal growth and to a severe 
osteoporosis phenotype (Xu et al., 1998). Importantly, only biglycan is expressed in 
endothelium of myofibers, peripheral nerves, and kidneys as well as in aorta (Bianco 
et al., 1990) and in blood vessels in the skin and brain (Salo et al., 2016), in kidneys 
(Schaefer et al., 2000), and in the liver (Högemann et al., 1997). 
In addition to their structural function, biglycan and decorin display various roles 
in cell signaling, in tumorigenesis and in promoting inflammation (Schaefer & 
Schaefer, 2010; Theocharis et al., 2016). Following sterile inflammation (tissue 
stress, injury, and cell death), both PGs are released from the ECM (Schaefer, 2014). 
Soluble biglycan and decorin are identified as danger-associated molecular patterns 
(DAMP) by innate immune cells, mainly macrophages, via the TLR2 and TLR4 
receptors (Schaefer, 2014; Frevert et al., 2018). Subsequently, the macrophages 
release proinflammatory cytokines and chemokines to attract more innate and 
adaptive immune cells (macrophages, neutrophils, B and T cells) to the site of 
infection. Examples of biglycan induced cytokines are TNF-α, MIP (macrophage 
inflammatory protein) -1α and -2, MCP (monocyte chemoattractant protein) -1, 
RANTES (regulated upon activation, normal T cell expressed and secreted), IL-1β, 
CCL (C-C motif chemokine ligand) 2 and 5, and CXCL (C-X-C motif chemokine 
ligand) 13 (Schaefer et al., 2005; Babelova et al., 2009; Moreth et al., 2010; Zeng-
Brouwers et al., 2014). The newly attracted immune cells amplify the local 
inflammatory response by synthesizing additional biglycan de novo which, in turn, 
leads to the release of more proinflammatory cytokines (Nastase et al., 2012). 
Interestingly, after an LPS injection mimicking a bacterial infection, soluble 
biglycan possibly increased the severity of the lung sepsis as seen by shorter survival 
time of the biglycan wildtype mice compared to the longer survival of the biglycan 
deficient mice (Schaefer et al., 2005). 
The host molecules, biglycan and decorin, are important for Borrelia 
pathogenesis. The adhesion of decorin-binding proteins (Dbp) A and B of Borrelia 
to decorin have been extensively studied in vitro and in vivo using Borrelia lacking 
either DbpA, DbpB, or DbpA and B (Guo et al., 1998; Brown et al., 1999; Shi et al., 
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2006; Shi et al., 2008a; Shi et al., 2008b; Fortune et al., 2014; Lin et al., 2014; Salo 
et al., 2015). If one or both adhesins were lacking, the overall virulence and 
infectivity of Borrelia were reduced (Shi et al., 2008a; Salo et al., 2015). Further, 
mice deficient of decorin were similarly infected with Borrelia than wildtype mice, 
except that the bacterial joint colonization and joint inflammation were decreased 
(Brown et al., 2001). Brown and colleagues suggested that Borrelia overcomes the 
decorin deficiency by adhering to another ligand, such as biglycan. Recently, the 
DbpA and B adhesins were shown to bind to biglycan in vitro (Salo et al., 2016). 
Interestingly, the interaction of biglycan and DbpA and B varied depending on the 
Borrelia genospecies and depending on the study conditions. The DbpA and B of B. 
garinii bound effectively biglycan under flow conditions mimicking the conditions 
when Borrelia is circulating in the human blood vessels. In contrast, under stationary 
conditions only DbpB of B. garinii and of B. burgdorferi ss bound strongly to 
biglycan. The DbpA and B of B. afzelii did not bind to biglycan neither under flow 
nor under stationary conditions. Despite the well-characterized interaction of 
biglycan and DbpA and B in vitro, the in vivo studies are important to establish the 
role of biglycan in the pathogenesis of Borrelia.  
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3 Aims 
The function of multiple Borrelia proteins and the interactions between Borrelia and 
host molecules are not completely understood in the pathogenesis of Lyme 
borreliosis. Further, the seroprevalence of Lyme borreliosis in the time prior to the 
characterization of the disease entity has not been studied. Hence, following aims 
were set to shed light on these questions. 
 
1. To study the role of Basic membrane protein D in the pathogenesis of 
Borrelia infection. 
2. To study the role of the host molecule biglycan in Borrelia infection in 
vivo. 
3. To study the historical seroprevalence and the associated risk factors of 
Lyme borreliosis in Finland. 
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4 Materials and Methods 
4.1 Bacterial experiments 
4.1.1 Bacterial strains and culture conditions (Studies I and II) 
The wildtype Borrelia strains, B. burgdorferi ss B31 and N40, B. garinii SBK40 and 
B. afzelii A91, were cultivated in BSK-II medium at 33°C under microaerophilic 
conditions (Table 5). Borrelia were counted after reaching the logarithmic growth 
phase with Neubauer chamber and phase-contrast microscope.  
Table 5.  Bacterial strains used in this study. The antibiotic selection is mentioned in the square 
brackets. 
Bacterial strain Special feature Reference Study 
B. burgdorferi ss B31  Isolated from a tick (Burgdorfer et al., 1982) I and II 
B. burgdorferi ss N40 Isolated from a tick (Anderson et al., 1990) II 
B. garinii SBK40 Isolated from skin biopsy (Heikkilä et al., 2002b) II 
B. afzelii A91 Isolated from skin biopsy (Heikkilä et al., 2002b) II 
E. coli BL21(DE3)pLys + BmpD 
[Cm] 
Transformed with pET-30 
Ek/LIC + bmpD/ B. 
burgdorferi ss B31 [Km] 
Study I I 
E. coli BL21(DE3)pLys + DbpA/ B. 
burgdorferi ss [Cm] 
Transformed with pET-30 
Ek/LIC + dbpA/ B. 
burgdorferi ss N40 [Km] 
(Salo et al., 2011) II 
E. coli BL21(DE3)pLys + DbpB/ B. 
burgdorferi ss [Cm] 
Transformed with pET-30 
Ek/LIC + dbpB/ B. 
burgdorferi ss N40 [Km] 
(Salo et al., 2011) II 
E. coli M15(pREP4) + DbpA/ B. 
garinii [Km] 
Transformed with pQE30 
+ dbpA/ B. garinii SBK40 
[Amp] 
(Heikkilä et al., 2002b) II 
E. coli M15(pREP4) + DbpB/ B. 
garinii [Km] 
Transformed with pQE30 
+ dbpB/ B. garinii SBK40 
[Amp] 
(Heikkilä et al., 2002a) II 
E. coli M15(pREP4) + DbpA/ B. 
afzelii [Km] 
Transformed with pQE30 + 
dbpA/ B. afzelii A91 [Amp] 
(Heikkilä et al., 2002b) II 
E. coli M15(pREP4) + DbpB/ B. 
afzelii [Km] 
Transformed with pQE30 + 
dbpB/ B. afzelii A91 [Amp] 
(Heikkilä et al., 2002a) II 
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The Escherichia coli strains used for cloning were DH5α and for expression of 
recombinant proteins were BL21(DE3)pLys (Novagen, Madison, WI, USA) and 
M15 (Qiagen, Hilden, Germany) (Table 5). E. coli were propagated in Luria Bertani 
(LB) medium or on agar plates under antibiotic selection of 30 µg/ml kanamycin 
(Km; Sigma-Aldrich), 34 µg/ml chloramphenicol (Cm; USB Corporation, 
Cleveland, USA) or 100 µg/ml ampicillin (Amp; Sigma-Aldrich) at 37°C. 
4.1.2 Proteinase K-assay (Study I) 
The localizations of proteins on the outer membrane or in the periplasmic space of 
Borrelia were detected by enzymatic degradation assay using proteinase K (Sigma-
Aldrich, Darmstadt, Germany). The B. burgdorferi ss B31 in the mid-logarithmic 
stage were washed twice with phosphate buffered saline (PBS) containing 5 mM 
MgCl2, and diluted to 1x108 bacteria/ml. Proteinase K was added to the bacterial 
cells at concentrations of 0, 50, 100 or 200 µg/ml at room temperature (RT) for 
one hour. The bacteria were washed twice with the aforementioned buffer before 
analyzing the bacterial lysate samples by Western blot as described below. 
4.2 Mouse experiments 
4.2.1 Mouse strains (Studies I and II) 
All animal studies were approved by the National Animal Experiment Board in 
Finland (permissions ESAVI/5507/04.10.07/2014 and ESAVI/6265/04.10.07/2017), 
and performed according to the 3R-principle (Replacement, Reduction, and 
Refinement) as well as according to relevant guidelines and regulations by the 
Finnish Act on the Use of Animals for Experimental Purposes and directives of the 
European Union. All mouse strains used in this study are listed in Table 6.  
Table 6.  Characteristics of mouse strains used in this study. 
 
Mouse strain Gene modification Sex Provider Study 
C3H/HeNHSd  Wildtype (WT) Female Envigo, Horst, The 
Netherlands 
I 
C3H/HeNHSd  Wildtype (WT) Female and 
male 
Envigo II 
C3H/HeNHSd  Biglycan knock-out 
(KO)  
Female and 
male 
Turku Center of Disease 
Modeling (TCDM), Turku, 
Finland 
II 
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In Study I, four-week-old wildtype (WT) female mice were used for the 
immunization and passive immunization study. In Study II, four-week-old WT or 
biglycan knock-out (KO) female and male mice were used for the infection studies. 
The KO mice in the C57BL/6 background (Xu et al., 1998) were kindly provided by 
Dr. Marian Young (National Institute of Dental and Craniofacial Research, 
Bethesda, MD, USA), and were backcrossed 7 generations into the C3H/HenHSd 
background (Envigo) by TCDM. The genotype of the WT and KO mice was verified 
by PCR as described in (Xu et al., 1998) by TCDM. The phenotypes of WT and KO 
were verified by RT-qPCR and immunohistochemistry as described below. 
4.2.2 BmpD immunization study (Study I) 
Mice (n=14) were subcutaneously immunized with 100 µl of solution containing 50 
µg BmpD in PBS diluted 1:1 with TiterMax Gold adjuvant (Sigma-Aldrich). The 
control mice (n=15) received 100 µl PBS diluted 1:1 with the adjuvant. Mice 
received one booster dose at day 21. Blood samples were collected from tail vein at 
day 14 and by cardiac puncture at day 28. The blood samples were collected in 
heparinized tubes and centrifuged 1000 x g at RT for ten minutes. The antibodies 
towards rBmpD in serum samples collected at days 14 and 28 day after immunization 
were measured with ELISA as described below.  
For passive immunization studies, mice were intravenously injected with (1) 5 
ml/kg mouse serum containing anti-BmpD antibodies, (2) serum from PBS 
immunized mice, or (3) 50 µl saline as a control pretreatment. After 48 hours, the 
BmpD immunized mice (n=12) and mock immunized mice (n=12) were infected 
intradermally with 105 B. burgdorferi ss B31. The positive control mice (n=10) were 
infected similarly. The negative control mice (n=4) received 100 µl PBS 
intradermally. The course of infection was followed by collecting ear biopsy samples 
at days 7, 11, 14 and 21 post-infection, and measuring the joint swelling in a 
blindfolded manner once a week. After four weeks post-infection, mice were 
euthanized, and ear, tibiotarsal joint, heart, bladder, and whole-blood specimens 
were collected. 
4.2.3 Borrelia infection of biglycan KO/WT mice (Study II) 
The biglycan KO mice (n = 7–8/ experiment) and WT mice (n = 7–8/ experiment) 
were intradermally infected with 105 B. burgdorferi ss N40, B. garinii SBK40 or B. 
afzelii A91. The infected mice were followed up for 28 days (experiment I) or 56 
days (experiments II–IV). The course of infection was followed by collecting ear 
biopsy samples at days 7, 11, 14, 21 and 42 post-infection depending on the 
experiment. The joint swelling was monitored in a blindfolded manner once a week. 
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After mice were euthanized, ear, tibiotarsal joint, heart, bladder, and whole blood 
specimens were collected. 
4.3 Analyses of mouse tissue specimens 
4.3.1 Borrelia culture (Studies I and II) 
The tissue samples of Borrelia infected and mock treated mice were cultured in 
BSK-II medium supplemented with 50 µg/ml phosphomycin (Sigma-Aldrich) and 
100 µg/ml rifampicin (Sigma-Aldrich) for six weeks. Every two weeks the growth 
of Borrelia in the tissue samples was monitored by dark-field microscopy. 
4.3.2 Histology and immunohistochemistry (Study II) 
For histologic examination, mouse tissue samples were fixed in 10% phosphate 
buffered formaldehyde, dehydrated in a graded ethanol series and embedded in 
paraffin and sectioned at 5 µm. Before paraffin embedding, tibiotarsal joint 
specimens were decalcified in EDTA. The tissue samples were stained with 
haematoxylin and eosin (H&E) for light microscopy using routine histology 
techniques. Further, heart specimens were stained with Weigert Van Gieson -method 
to highlight the collagen fibers in case of heart fibrosis. 
The inflammation in joints (experiments I–IV) and in hearts (experiments I and 
II) were evaluated in sagittal tibiotarsal joint and heart sections by an experienced 
pathologist blinded to the experimental protocol. The joint inflammation was graded 
from no inflammation to severe inflammation by scoring the synovial proliferation 
and active and chronic inflammation (numerical scale 0 to 6). The myocardial 
inflammation and fibrosis were graded from no inflammation or fibrosis to severe 
inflammation with fibrosis (numerical scale 0 to 8). 
For immunohistochemistry, tissues were processed until paraffin embedding as 
for histological analysis. For biglycan staining, the tissue samples were first digested 
with 0.0045 U/ml chondroitinase ABC (Sigma-Aldrich), and then stained with a 
rabbit IgG polyclonal antibody LF-159 (1:500; Kerafast, Boston, USA). 
Immunodetection was performed using the avidin-biotin complex method (Sigma-
Aldrich), diaminobenzidine was used as the chromogen, and finally, the sections 
were counterstained with H&E. 
4.3.3 DNA extraction and qPCR (Studies I and II) 
The bacterial load in tissue specimens was analyzed by quantitative PCR (qPCR) as 
described in (Ivacic et al., 2007). The total DNA in mouse tissue samples were 
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extracted with the High Pure PCR Template Preparation Kit (Roche Diagnostics). 
Then, a 102 bp product of the ospA gene of Borrelia was amplified using the primers 
listed in Table 7, and with LightCycler 480 Probes master kit (Roche Diagnostics) 
and LightCycler 480 II equipment (Roche Diagnostics). The protocol contained the 
following steps: 1) initial denaturation at 95 °C for 5 minutes, 2) 45 cycles of 
denaturation at 95 °C for 10 seconds, primer annealing at 58 °C for 10 seconds and 
extension at 72 °C for 12 seconds, 3) melting curve, and 4) cooling at 40 °C. To 
calculate the actual Borrelia load in each sample, the bacterial load was compared 
to the standard curve of 100 to 1,000,000 bacteria. The samples were analyzed three 
times. The samples were accepted as positive, when the bacterial load could be 
analyzed at least two times. The data were expressed as the number of bacterial 
genomes per 100 ng of extracted total DNA. 
4.3.4 RNA extraction and RT-qPCR analysis (Study II) 
The biglycan mRNA expression in mouse tissues was detected by RNA extraction 
and by reverse transcriptase quantitative PCR (RT-qPCR). Lung tissue samples of 
uninfected biglycan KO and WT mice and multiple tissues from uninfected and B. 
garinii infected WT mice were collected and stored in RNAlater (Qiagen, Hilden, 
Germany) at -20 °C. The total RNA was extracted by RNeasy Mini kit (Qiagen), and 
reverse transcribed to cDNA by QuantiTect Rerverse Transcription Kit (Qiagen) 
according to manufacturer’s protocols.  
The LightCycler 480 SYBR Green I Master mix (Roche Diagnostics) and 
Light-Cycler 480 II equipment (Roche Diagnostics) were used to detect the gene 
expression of biglycan and the reference gene glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) with primers listed in Table 7. The protocol included the 
following steps: 1) pre-incubation at 50 °C for 2 minutes, 2) initial denaturation at 
95 °C for 10 minutes, 3) 40 cycles of denaturation at 95 °C for 10 seconds, primer 
annealing at 60 °C for 10 seconds and extension at 72 °C for 10 seconds, 4) melting 
curve, and 5) cooling at 40 °C. The biglycan mRNA abundance was determined 
from the quantification cycle (Cq) for biglycan and normalized against the Cq for 
GAPDH using the 2-ΔΔCq method (Rao et al., 2013). Data were expressed as fold 
changes 
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Table 7.  Primers used in this study. 
Primer Sequence 5’−3’ Reference 
bgn wildtype allele forward for 
genotyping 
CAGGAACATTGACCATG (Xu et al., 1998)  
bgn wildtype allele reverse for 
genotyping 
CTTCAGTGCCATGTGTCCTTTC (Xu et al., 1998) 
bgn knock-out allele forward for 
genotyping 
CAGGAACATTGACCATG (Xu et al., 1998) 
bgn knock-out allele forward for 
genotyping 
CCTCGCACACATTCCACATCCA (Xu et al., 1998) 
bgn forward for RT-qPCR  ATTGCCCTACCCAGAACTTGAC (Calmus et al., 
2011)  
bgn reverse for RT-qPCR GCAGAGTATGAACCCTTTCCTG (Calmus et al., 
2011) 
gapdh forward for RT-qPCR CTCACAATTTCCATCCCAGAC  (Calmus et al., 
2011) 
gapdh reverse for RT-qPCR GTTCGCTGCACCCACAAAAA (Calmus et al., 
2011) 
ospA forward for qPCR AATATTTATTGGGAATAGGTCTAA (Ivacic et al., 2007) 
ospA reverse for qPCR CACCAGGCAAATCTACTGA (Ivacic et al., 2007) 
ospA probe for qPCR 6-FAM-TTAATAGCATGTAAGCAA 
AATGTTAGCA-XT-PH 
(Ivacic et al., 2007) 
T7 promoter #69348-3 TAATACGACTCACTATAG Novagen 
T7 terminator #69337-3 GCTAGTTATTGCTCAGCGG Novagen 
bgn ~ biglycan, gapdh ~ glyceraldehyde 3-phosphate dehydrogenase, ospA ~ outer surface protein 
A, (RT)-qPCR ~ (reverse transcriptase) quantitative polymerase chain reaction. 
4.3.5 Mouse serology (Studies I and II) 
The blood samples of mice were collected, centrifuged at 1000 x g (Study I) or 6000 
x g (Study II) at RT for 10 minutes, and the resulting sera were stored at -20 °C. The 
IgG antibodies in mouse serum samples towards whole-cell sonicate antigen of B. 
burgdorferi ss B31 (ATCC 35210) (Borrelia WCS), and towards recombinant 
proteins (rBmpD, rDbpA or rDbpB of B. burgdorferi ss N40, B. garinii SBK40 or 
B. afzelii A91) were measured with in-house ELISA as described in Table 8. 
Briefly, the enhanced binding 96-well microtiter plates (Thermo Fisher 
Scientific, Waltham, USA) were coated with Borrelia WCS (Viljanen & Punnonen, 
1989) or recombinant proteins. After coating, the wells were washed with aqua 
supplemented with 0.05% Tween 20 (Aqua-T; Merck) and saturated with 1% normal 
sheep serum (NSS; Bio Karjalohja Oy, Karja-Lohja, Finland), and washed as above. 
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The mouse serum samples were added to the wells, incubated, and washed as above. 
The secondary antibody horseradish peroxidase (HRP) conjugated goat anti-mouse 
IgG (Santa Cruz Biotechnologies) was added to the wells, incubated and washed as 
above. The ortho-phenylenediamine (OPD) substrate solution (Kem-En-Tec 
Diagnostics, Taastrup, Denmark) was added to the wells, and incubated as above. 
The reaction of the substrate solution was stopped with H2SO4. Finally, the 
absorbance was measured at 492 nm with Multiskan EX spectrophometer (Thermo 
Fisher Scientific). All samples were measured in duplicates or quadruplicates. The 
results were expressed as OD492 values. 
Table 8.  Details of ELISA protocol for mouse serology. The abbreviations are explained in the 
main text. 
Solutions Concentration/ 
Dilution factor 
Volume 
(µl) 
Temperature 
(⁰C) 
Time 
Coating Borrelia WCS in 
PBS 
20 µg/ml 120 37 overnight 
recombinant protein 
in PBS 
10 µg/ml 120 37 overnight 
Wash Aqua-T  200 RT 3 times 
Blocking NSS-PBS 1% 150 37 1 hour 
Wash Aqua-T  200 RT 3 times 
Serum 
sample 
Mouse serum in 
NSS-PBS 
1:100 100 37 1 hour 
Wash Aqua-T  200 RT 3 times 
Secondary 
antibody 
HRP conjugated 
goat anti-mouse IgG 
in NSS-PBS 
1:8,000 100 37 1 hour 
Wash Aqua-T  200 RT 3 times 
Substrate OPD   100 37 15–45 
minutes 
Stop H2SO4 0.5 M 100 RT  
4.3.6 Multiplex cytokine analysis (Study II) 
The levels of multiple cytokines in mouse plasma samples were measured with 
Luminex 200 equipment (Luminex, Austin, USA) and a customized MILLIPLEX 
MAP Mouse Cytokine/Chemokine MCYTOMAG-70K (Merck Millipore, Billerica, 
USA) according to manufacturer’s protocol. The results of each cytokine were 
calculated based on a standard curve using the xPONENT software version 3.1. 
(Luminex). The cytokine analytes measured were IL-1β, MCP-1/CCL2, MIP-
1α/CCL3, RANTES/CCL5, TNFα and MIP-2/CXCL2. 
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4.4 Protein experiments 
4.4.1 Cloning of recombinant proteins (Studies I and II) 
A synthetic bmpD gene based on the sequence of B. burgdorferi ss B31 (Gene ID: 
1195222; residues 18–323) was generated by a commercial vendor (Integrated DNA 
Technologies, Leuven, Belgium) with BglII and NotI recognition sites at both ends.  
The bmpD gene was designed not to include the signal peptide (residues 1–17), and 
the codons were optimized for E. coli. The bmpD gene and the pET-30 Ek/LIC -
vector (Novagen) were digested with BglII and NotI (Thermo Scientific, Waltham, 
MA, USA), and ligated with the T4 DNA ligase (Novagen) according to the 
manufacturer’s cloning protocol (Novagen). The resulting fusion construct 
contained a hexa-histidine tag at the N-terminal of the recombinant protein. The 
resulting plasmid was verified by sequencing using the T7 promoter and terminator 
primers (Novagen; Table 7). The plasmid was transformed into E. coli DH5α for 
plasmid amplification, and subsequently to E. coli BL21 (DE3)pLys (Novagen) for 
protein expression. 
The E. coli BL21(DE3)pLys -strains expressing DbpA or DbpB of B. 
burgdorferi ss N40 were cloned in the pET-30 Ek/LIC -vector as described by (Salo 
et al., 2011). The E. coli M15(pREP4) strains expressing DbpA or DbpB of B. garinii 
SBK40 and B. afzelii A91 in the pQE-30 vector were kindly provided by Pekka 
Lahdenne (University of Helsinki, Finland). 
4.4.2 Purification of proteins by affinity chromatography (Studies 
I and II) 
All recombinant proteins, rBmpD, rDbpA and rDbpB of B. burgdorferi ss N40, B. 
garinii SBK40 and B. afzelii A91, were purified by affinity chromatography. For 
expression of recombinant proteins, an overnight E. coli culture was diluted 1:20 
(rBmpD) or 1:50 (rDbps) in LB medium with appropriate antibiotic selection under 
vigorous shaking at 37°C. After reaching the OD600 of 0.6, the protein expression 
was induced by adding 1 mM isopropyl-β-D-1-thiogalactopyranoside to the bacterial 
culture. After induction, the culture was grown for 3–4 hours, and the bacteria were 
collected by centrifugation at 4000 x g for 15 minutes at 4°C. The bacterial cell pellet 
was stored at -80°C until purification. 
The bacterial pellet was suspended in buffer A (50 mM Na2HPO4/NaH2PO4 /300 
mM NaCl; pH 8.0) supplemented with 1 mM phenylmethylsulfonyl fluoride and 1 
U/µl benzonase (EMD Millipore, Billerica, MA, USA), lysed by ultrasound 
sonication, and centrifuged by 10,000 x g at 4°C for 30 minutes. The overexpressed 
protein in the supernatant was allowed to adhere to a nickel-nitrilotriacetic acid (Ni-
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NTA) resin column (Qiagen, Hilden, Germany) at 4°C for one hour, and the column 
was washed with three column volumes (CV) of buffer A containing 10 mM 
imidazole, one CV of buffer A containing 30 mM imidazole, and with 6 ml of buffer 
A containing 50 mM imidazole. The recombinant proteins were eluted with 6 ml and 
12 ml buffer A containing 100 and 200 mM imidazole, respectively, at 4°C. The 
eluted protein fractions were dialyzed against PBS at 4°C, and concentrated with 10 
kDa cut-off Amicon ultracentrifugal device (EMD Millipore, Burlington, MA, 
USA). The protein concentration was measured spectrophotometrically. 
4.4.3 Purification of the ligand-free protein (Study I) 
In order to remove the endogenously bound ligand, rBmpD was denaturated and 
refolded (Deka et al., 2006). rBmpD was first processed by affinity chromatography 
as described above, but instead of elution, the Ni-NTA bound protein was incubated 
with 10 ml of denaturation buffer B (8 M urea/ 100 mM Tris-HCl; pH 8.5) at RT for 
one hour. The Ni-NTA column was washed with 20 ml of buffer B and with buffer 
B diluted 1:1 and 1:3 with buffer C (20 mM Tris-HCl/ 20 mM NaCl/ 20 mM 
imidazole, pH 8.5), and with 20 ml buffer C. The resin was incubated with 10 ml of 
buffer C at RT for one hour. The refolded protein was eluted with 5 ml of buffer D 
(20 mM Tris-HCl/ 20 mM NaCl/ 200 mM imidazole, pH 8.5), concentrated, and 
purified by size exclusion chromatography (SEC) as described below. 
4.4.4 Purification by size exclusion chromatography (Study I) 
To exclude E. coli derived impurities from the native and ligand-free rBmpD 
solutions, size exclusion chromatography (SEC), an additional purification step, was 
performed before the crystallization and ligand-binding assays. The rBmpD was 
purified with ÄKTA pure chromatography system (GE Healthcare Life Sciences, 
Chicago, USA) and SuperdexTM 75 10/300 GL column (GE Healthcare Life 
Sciences). The protein buffer was exchanged to 50 mM Tris-HCl (pH 8.0). The 
fractions of the elution peaks were analyzed by SDS-PAGE stained with Simply blue 
as described below. 
4.4.5 Crystallization, X-ray data collection, and refinement 
(Study I) 
The rBmpD formed crystals by the sitting drop vapor diffusion method in 2:1 
reservoir solution of 0.2 M sodium chloride, 0.1 M Tris, 20% (w/v) PEG 6000 (pH 
8.0) supplemented with 15% MPD (2-methyl-2,4-pentanediol) as cryoprotectant. 
The crystals diffracted to 1.43 Ångström (Å) resolution at the beamline ID30A-3 
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European Synchrotron Radiation Facility (ESRF, Grenoble, France). Datasets were 
collected and processed with XDS, and the structure was solved by molecular 
replacement with Phaser using T. pallidum PnrA (PDB ID: 2FQY) as search model. 
The model building of the amino acid residues corresponding to BmpD was 
performed in Coot and refined by phenix.refine. The structure of adenosine was fitted 
into the electron density observed in the substrate-binding cleft in the initial BmpD 
model. The refinement statistics for the final refined model are listed in Study I, 
Table 1. 
4.4.6 SDS-PAGE and Western blot (Study I) 
The protein or bacterial lysate samples were boiled at 95°C for 8 minutes with 
sample buffer before running the samples on a 10% Bis-Tris polyacrylamide gel 
(PAGE, NuPage®, Life Technologies, Carlsbad, CA, USA) with MES buffer 
containing sodium dodecyl sulfate (SDS) at 200 V for 50 minutes. For protein 
detectetion, the SDS-PAGE was stained with Simply blue (Invitrogen, Carlsbad, CA, 
USA) at RT for one hour. The stained gel was imaged with LicorOdyssey imaging 
system (Licor Biotechnology, Bad Homburg, Germany). 
For Western blotting, the samples on SDS-PAGE were blotted to a 0.2 µm ni-
trocellulose membrane (Whatman, Dassel, Germany) at 30 V for one hour. The 
membranes were blocked with 5% skim milk in PBS at 4°C overnight. The 
membranes were incubated either with serum samples of LB positive (n=3) or non-
LB patients (n=3), with polyclonal rabbit anti-BmpD serum, polyclonal rabbit anti-
DbpB serum, polyclonal p41 antibody or with monoclonal mouse anti-OspA 
antibody at RT for one hour. After rinsing the membrane with PBS supplemented 
with 0.05% Tween 20 (PBST; Merck), the membranes were incubated with an 
appropriate secondary antibody listed in Table 9 at RT for one hour. The bound 
antibodies were detected with WesternBright ECL HRP substrate (Advansta, San 
Jose, USA) and Odyssey Fc imaging system (Licor Biotechnology). The serum 
samples and antibodies were diluted in PBST supplemented with 5% skim milk with 
dilution factors listed in Table 9. 
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Table 9.  Antibodies used in Western blots in this study. The dilution factors are indicated in the 
parentheses. 
Sample Primary 
antibody  
Manufacturer Secondary 
antibody  
Manufacturer 
rBmpD Human serum 
sample (1:100) 
 HRPa 
conjugated 
rabbit-anti-
human IgG 
(1:1,000)  
DAKO Agilent 
Technologies, 
Santa Clara, 
CA, USA 
rBmpD or 
Borrelia lysate 
Rabbit 
polyclonal anti-
BmpD serum 
(1:1,000) 
Custom made 
by Harlan 
Laboratories, 
Leicester, UK 
HRP conjugated 
goat-anti-rabbit 
IgG (1:5,000) 
Santa Cruz 
Biotechnology, 
Santa Cruz, CA, 
USA 
Borrelia lysate Rabbit 
polyclonal anti-
DbpB serum 
(1:1,000) 
Custom made 
by Medprobe, 
Oslo, Norway 
HRP conjugated 
goat-anti-rabbit 
IgG (1:5,000) 
Santa Cruz 
Biotechnology 
Borrelia lysate Rabbit 
polyclonal p41 
(1:1,000) 
Aviva Systems 
Biology, San 
Diego, CA, USA 
HRP conjugated 
goat-anti-rabbit 
IgG (1:5,000) 
Santa Cruz 
Biotechnology 
Borrelia lysate Mouse 
monoclonal 
OspA (1:2,500) 
H5332; kindly 
provided by Dr. 
Sven 
Bergström, 
University of 
Umeå, Sweden 
HRP conjugated 
goat anti-mouse 
IgG (1:5,000) 
Santa Cruz 
Biotechnology 
aHRP~ Horseradish peroxidase. 
4.4.7 Microscale thermophoresis (Study I) 
Microscale thermophoresis (MST) (Seidel et al., 2013) was used to study the binding 
of ligands to the ligand-free rBmpD using the label-free approach. Adenosine, 
inosine, guanosine, ribose, and xanthosine (Sigma-Aldrich) were dissolved in 50 
mM Tris-HCl (pH 8.0). A 24-point serial dilution of a ligand was mixed with LF-
rBmpD (final concentration 500 nM). The concentration of the ligands ranged from 
5 mM to 1.2 nM. Samples were filled into Zero Background Treated Standard 
Capillaries (MO-AZ002, NanoTemper Technologies, Munich, Germany) and 
measured with Monolith.NT115 LabelFree equipment (NanoTemper Technologies) 
using 60% LED-power and medium MST-power. The data were analyzed by 
MO.affinity software (Nanotemper Technologies) and GraphPad Prism version 7.0 
(GraphPad Software, San Diego, CA, USA). 
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4.4.8 Liquid chromatography-mass spectrometry (Study I) 
Liquid chromatography-mass spectrometry (LC-MS) was used to determine the 
small molecule bound to rBmpD with the modified analytical method of (Ren et al., 
2008). First, rBmpD and for comparison LF-rBmpD samples were heated at 95 ⁰C 
for 10 minutes, and centrifuged with 21,000 x g for 30 minutes.   
The resulting supernatant was directly used in the Agilent 1100 series liquid 
chromatography system (Agilent Technologies, Santa Clara, USA). Separations 
were conducted using gradient elution on a SunFire™ C18 analytical column (2.1 × 
150 mm, particle size 3.5 µm, Waters, USA). The mobile phases were 0.1% formic 
acid in water (A) and 0.1% formic acid in methanol (B). The gradient conditions 
were 5% of B (0–12 min), from 5% to 80% (12–13 min), 80% (13–18 min), from 
80% to 5% (18–18.5 min) and 5% (18.5–25 min). The flow rate was 0.25 ml/min. 
Retention times for adenosine and inosine were 4.7 and 7.7 min, respectively (Study 
I, Figure 4A). 
Mass spectrometric detection was performed in selected-ion monitoring mode 
(SIM) with a single quadrupole mass spectrometer (HP 1100 LC/MSD). Ionization 
was based on electrospray ionization in positive mode. The capillary voltage was 4.0 
kV and the drying gas temperature 350 °C. The selected ions for adenosine and 
inosine were m/z 268.0 and 269.0, respectively (Study I, Figure 4A). These masses 
correspond to their protonated molecules [M+H]+. Adenosine was also detected as 
m/z 269.0 due to its isotopic distribution. 
4.4.9 Thermofluor (Study I) 
Thermofluor is a fluorescence-based thermal stability assay for biophysical ligand 
screening (Boivin et al., 2013; Bai et al., 2019). 25 µM of LF-rBmpD was mixed 
with 50 µM of ligand (adenosine, inosine, guanosine, ribose and xanthosine) and 
SYPRO Orange (1:55, Life Technologies, Carlsbad, USA). The protein-ligand -mix 
was heated from 20 to 98 °C with stepwise increments of 0.01 °C per second. The 
resulting fluorescence signals were measured in triplicates with LightCycler 480 
equipment (Roche) at 465 nm excitation and 580 nm emission wavelengths. 
4.5 Analyses of human serum samples  
4.5.1 Study samples and ethics (Study III) 
Serum samples (n=994) collected during the Finnish Mobile Clinic Health Survey 
(FMC) from 1968 to 1972 were used for the serological study. The FMC was a cross-
sectional health survey of over 50,000 voluntary study participants aged 15 years or 
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older where data was collected in 31 municipalities in different parts of Finland from 
1966 to 1972 (Knekt et al., 2017). 
As the study was conducted in the time preceding the current legislation on ethics 
in medical research, agreeing to participate in the study was taken to denote as 
informed consent form (Knekt et al., 2017). From the study participants, a wide-
ranging health questionnaire, physical examinations, X-ray examinations, and 
electrocardiograms were included in the FMC survey data as well as urine and serum 
samples were collected. 
4.5.2 Quality check of the historical serum sample collection 
(Study III) 
The historical human serum samples were stored in -20°C for 50 years. Before 
analysis, serum samples were thawed at RT and visually inspected. All samples 
contained yellowish serum with white precipitate. Hence, serum samples were 
always vortexed before pipetting to well plates. For initial sample quality check, the 
presence of IgG levels in 41 randomly selected sera was checked using an in-house 
varicella zoster virus (VZV) ELISA (Alanen et al., 2005), and 50 serum samples 
determined negative by the Borrelia WCS screening test were tested with 
recomBead IgG 2.0. 
4.5.3 Serology (Study III) 
The human serum samples were screened for Borrelia antibodies with ELISA. The 
ELISA protocol was similar to the one used for the mouse samples described above. 
Briefly, Borrelia WCS coated well plates were incubated, washed, blocked as 
described above. Human serum samples diluted to 1:100 in NSS-PBS and standard 
samples of 0 and 100 enzyme immunoassay units (EIU) were added to the wells. The 
IgG levels in the human samples were detected with secondary antibody goat anti-
human IgG (Calbiochem, Darmstadt, Germany) diluted 1:20,000 in NSS-PBS and 
the p-nitrophenyl phosphate substrate (Reagena, Toivakka, Finland). The reaction 
was stopped with 1 M NaOH. All samples with IgG levels of ≥20 EIU were further 
tested with the second-tier test C6 Lyme ELISA (Immunetics, Boston, MA, USA). 
The screening-positive serum samples were added to wells coated with synthetic 
C6 peptide (a conserved region of the VlsE protein of Borrelia) and the ELISA was 
performed according to the protocol of the manufacturer (Immunetics, Oxford, UK). 
The serum samples were determined with the resulting Lyme index (LI) as negative 
(LI ≤0.9), borderline (LI = 0.91–1.09) or positive (LI ≥1.10). All samples with 
borderline or positive result (LI ≥0.91) were further tested with a third tier test. 
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All samples with positive C6 peptide result, or samples with negative by C6 
peptide ELISA, but with Borrelia WCS IgG result ≥40 EIU, were tested with 
recomBead IgG 2.0 immunoassay (Mikrogen, Neuried, Germany) according to the 
protocol of the manufacturer.  
The IgG levels in serum samples towards thirteen different antigens (p100, VlsE, 
p58, p39, OspA and OspC) of five Borrelia genospecies (B. burgdorferi ss, B. 
garinii, B. afzelii, B. bavariensis, and B. spielmanii) were detected using magnetic 
polystyrene beads (recomBead Borrelia beads) coated with the individual antigens, 
the MAGPIX System with Luminex® xPONENT software, and the Mikrogen 
recomQuant evaluation software. Using the test result, serum samples were 
determined as negative (test results 0–2 points), borderline (3 points) or positive (> 
3 points). 
4.6 Statistics (Studies I–III) 
In Studies I and II, data with continuous variables of non-normality were analyzed 
with Kruskal-Wallis test or Mann Whitney-U test, and the results were corrected 
with Steel-Dwass or Sidak’s post hoc test. Data with categorical variables were 
analyzed with Fisher’s Exact Test. 
In Study III, the serology results were combined with background data of the 
study participants to estimate the overall seroprevalence and the risk factors with 
univariate and multivariable logistic regression. Further, the self-reported diseases, 
symptoms and health-related questions associated with LB seropositivity were 
analyzed with univariate logistic regression and with single variable logistic 
regression adjusted for sex, age groups, and regions. The results are presented as 
odds ratio (OR) with 95% confidence intervals (CI).   
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5 Results 
5.1 BmpD – A novel purine nucleoside-binding 
protein identified (Study I) 
5.1.1 BmpD is not an outer surface protein  
The cellular localization of BmpD in Borrelia was detected by enzymatic 
degradation with proteinase K, which cleaves bacterial surface proteins. The signals 
of the well-characterized outer membrane proteins OspA and DbpB decreased with 
increasing concentration of proteinase K, whereas the signals of BmpD and of the 
known periplasmic flagella remained visible at equal levels despite the addition of 
proteinase K (Figure 10). Thus, BmpD is not expressed on the outer surface of 
Borrelia. 
     
5.1.2 Anti-BmpD do not protect from Borrelia infection 
We showed that Borrelia expresses BmpD during infection in the mammalian host 
as antibodies towards BmpD were detected in sera of LB patients, but not in serum 
samples negative for LB (Study I, Figure 7A). Also, mice generated antibodies 
against BmpD (Study I, Figure 7B). However, our results indicated that the BmpD 
antibodies were not protective against Borrelia infection (Table 10). All mice 
immunized with BmpD antibodies became infected after B. burgdorferi ss B31 
challenge as evidenced by Borrelia positive tissue cultures (Table 10), significant 
Figure 10. Cellular localization of BmpD in B. 
burgdorferi ss B31. Detection of BmpD, Outer 
surface protein A (OspA), Decorin binding protein 
B (DbpB) and flagellin by Western blot after 
incubating bacterial cells with proteinase K at 
concentrations of 0, 50, 100, or 200 μg/ml. 
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joint swelling, detection of Borrelia DNA in the investigated tissues, and by 
significant antibody response against Borrelia (Study I, Figure 8A-C). The infection 
was similar in the study groups of mock immunized mice and positive control mice. 
The mice injected with PBS only remained uninfected. 
Table 10.  Results of the mouse immunization study. Number of Borrelia positive mice analyzed 
by tissue culturing. 
Study group (n) Borrelia positive mice at 28 days post-infection  
BmpD immunized (12) 12/12 
Mock immunized (12) 12/12 
Positive control (10) 10/10 
Negative control (4) 0/4 
5.1.3 Crystal structure of BmpD  
Our study revealed the crystal structure and function of BmpD derived from B. 
burgdorferi ss B31 (Figure 11). The rBmpD crystallized in 50 mM Tris-HCl (pH 
8.0) buffer. The 3D crystal structure of BmpD was successfully solved after 
computational refinement of the X-ray diffraction data (Study I, Figure 3 and Table 
1). The structure of BmpD consisted of two domains with a ligand-binding cleft 
between the two domains (Figure 11). The residues 8–115 and 243–269 formed the 
N-terminal domain with six beta strands and four alpha helices, whereas residues 
116–242 and 270–323 formed the C-terminal domain with six beta strands and six 
alpha helices. The two domains were linked together with three connecting loops. 
The existing ligand-binding site between the domains was occupied with a bound 
ligand (close-up in Figure 11). The endogenously bound ligand was probably 
obtained from the cytoplasm of the protein expression host E. coli as no ligand was 
added to the growth medium. The electron density of the ligand-binding site 
indicated that the bound ligand was a purine nucleoside, either adenosine or inosine. 
Thus, the BmpD crystal structure revealed the function of BmpD as a substrate-
binding protein of a bacterial ABC transporter. The structure of B. burgdorferi ss 
B31 BmpD is deposited with the accession code 6SHU into the Protein Data Bank 
(http://www.rcsb.org/). 
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Figure 11.  The crystal structure of B. burgdorferi ss B31 BmpD bound to adenosine (white sticks). 
The interactions between BmpD and adenosine are shown in the close-up, with the 
interacting residues shown as green sticks and water molecules as red spheres. Figure 
by Mia Åstrand. 
5.1.4 BmpD binds to purine nucleosides 
Further, we discovered that BmpD binds to purine nucleosides. First, the LC-MS 
analysis revealed that BmpD bound to adenosine by (Figure 11 and Study I, Figure 
4B). The amount of adenosine was significantly decreased after denaturing and 
refolding of BmpD (Study I, Figure 4C). Later, the MST results showed that BmpD 
also bound to inosine (Study I, Figure 5). 
Also, the aforementioned results were supported by a ligand-screening assay 
with thermofluor (Figure 12). LF-rBmpD combined with adenosine lead to a melting 
temperature shift of approximately 10 ⁰C compared to LF-rBmpD alone. The 
thermofluor results also suggested that inosine and guanosine could bind to LF-
rBmpD as the melting temperature shifted approximately 5 ⁰C compared to the LF-
rBmpD alone. However, BmpD binding to guanosine could not be detected by MST 
as guanosine exhibited autofluorescence. Xanthosine and, as expected, the negative 
control ligand ribose did not change the melting temperature of LF-rBmpD. 
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Figure 12.  Ligand-binding assay with thermofluor. The melting curves of ligand-free recombinant 
BmpD (LF-rBmpD) alone and combined with purine nucleoside ligands and ribose are 
shown with the respective melting temperature in the parentheses. The mean melting 
temperature was calculated from three independent binding curves. Fnorm ~ 
normalized fluorescence. 
5.2 Biglycan has a role in Borrelia infection (Study II) 
5.2.1 Borrelia infection is genospecies-dependent 
First, we generated a biglycan KO mice in the Borrelia infection susceptible 
C3H/HeNHSd background (Barthold et al., 1990). The genotype and phenotype of 
the novel KO mouse model was verified by RT-qPCR and immunohistochemistry. 
The KO mice were smaller and lightweight compared to the WT mice (Study II, 
Figure 1A). On the mRNA and tissue level, biglycan was neither produced in the 
lung tissues nor detected in the blood vessel walls of KO mice (Study II, Figure 1B-
C). Then, the KO and WT mice were similarly infected either with representative 
strains of B. burgdorferi ss, B. garinii or B. afzelii. The infection and dissemination 
was followed up to 56 days. 
The B. burgdorferi ss was infectious in KO and WT mice (Table 11). Borrelia 
were detected and quantified in all tissues of both mouse genotypes by culture and 
qPCR (Study II, Table 1). The loads of Borrelia were at equal levels in the following 
tissues of KO and WT mice; in the ear biopsy samples (at days 7, 10, 14, 21, 28, 42, 
and 56), in the heart and bladder (at days 28 and 56), and in the joints (at day 28) 
(Study II, Figure 3A-B). The bacterial load was significantly higher in the joints of 
KO mice than in WT mice at day 56 (Study II, Figure 3A-B). Further, B. burgdorferi 
ss infected KO and WT mice generated high antibody levels towards Borrelia WCS, 
rDbpA, and rDbpB, and developed visible joint swelling (Study II, Figures 4A-C 
and 5A-B). 
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Table 11.  Comparison of the results of Borrelia interaction to biglycan in vitro (Salo et al., 2016) 
and in vivo (Study II). The qualitative analysis shows the intensity of Borrelia binding to 
biglycan in cell adhesion assays and the virulence of Borrelia in biglycan knock-out (KO) 
and wildtype (WT) mice indicated as plus and minus the brackets.The quantitative 
analysis shows the number of Borrelia positive mice analyzed by tissue culturing.  
 In vitro study (Salo et al., 
2016) 
In vivo study (Study II) 
Borrelia strain cells expressing biglycan biglycan KO 
mice 
WT mice 
B. burgdorferi ss (++) 15/15 (++) 15/15 (++) 
B. garinii (++) 7/7 (++) 7/8 (++) 
B. afzelii (-) 0/8 (-) 5/8 (+) 
Negative control (-) 0/12 (-) 0/13 (-) 
++ ~ strong binding/ high virulence, + ~ weak binding/ low virulence, - ~ no binding/ avirulent. 
Similarly to B. burgdorferi ss, B. garinii also infected and disseminated in the 
KO and WT mice (Table 11). Starting from day 28, Borrelia were detected and 
quantified by culture and qPCR in all tissues of both mouse genotypes, except for 
one KO mouse (Study II, Table 1). The loads of Borrelia were at equal levels in the 
following tissues of KO and WT mice; in the ear biopsy samples (at days 28, 42, and 
56), in the heart, bladder, and joints (at days 28 and 56) (Study II, Figure 3C). At day 
28, the KO mice harbored significantly higher amount of Borrelia in the ear than the 
WT mice (Study II, Figure 3C). Further, B. garinii infected KO and WT mice 
generated moderate antibody levels towards Borrelia WCS, and high antibody levels 
towards the rDbpA and rDbpB (Study II, Figure 4A-C). The B. garinii caused only 
moderate joint swelling in both genotypes with moderate and high joint 
inflammation in KO and WT mice, respectively (Study II, Figures 5C and 6A). 
In contrast to the results of B. burgdorferi ss and B. garinii, B. afzelii was not 
infectious in KO mice (Table 11). All tissues of the B. afzelii infected KO mice 
collected throughout and at the end of the study remained negative by Borrelia 
culture and no bacterial genomes were detected by qPCR (Study II, Table 1 and 
Figure 3D). Further, no antibodies towards Borrelia WCS, rDbpA or rDbpB were 
detected in the KO mice (Study II, Figure 4A-C).  
Also, B. afzelii displayed low virulence in WT mice as only 5 of 8 became 
infected as investigated by tissue culture and qPCR (Study II, Table 1).  The bacterial 
loads in the ear biopsy samples (at days 28 and 56) and in the heart, bladder and joint 
of WT mice were significantly higher than in the negative tissues of KO mice (Study 
II, Table 1 and Figure 3D). The B. afzelii infected WT mice had moderate antibody 
levels towards Borrelia WCS and rDbpB, and high levels towards rDbpA (Study II, 
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Figure 4A-C). Only a small increase of joint swelling and no joint inflammation were 
detected in the KO and WT mice (Study II, Figures 5D and 6A).  
In summary, the infection study revealed that B. burgdorferi ss and B. garinii 
were able to establish infection and disseminate in biglycan KO mice, although the 
in vitro results indicated that B. burgdorferi ss and B. garinii bound strongly to 
biglycan (Table 11). Unexpectedly, B. afzelii was non-infectious in the biglycan KO 
mice, while the in vitro results suggested that B. afzelii did not bind to biglycan 
(Table 11). Thus, we concluded that the infection and dissemination of Borrelia in 
the biglycan deficient mice were depended on the Borrelia genospecies.  
5.2.2 Host inflammatory reaction is mouse genotype-dependent 
Interestingly, the infection study also revealed that the Borrelia infection resulted in 
different host inflammatory responses depending on the mouse genotype. 
The joint inflammation of B. burgdorferi ss infected biglycan KO mice resulted in a 
high scoring at day 28 and remained continuously elevated at day 56 (Study II, 
Figure 6A and C). Meanwhile, the WT mice displayed visible arthritis at day 28, but 
the arthritis score had statistically significantly lowered at day 56. The heart 
inflammation of B. burgdorferi ss infected KO and WT mice was at equal levels at 
days 28 and 56 (Study II, Figure 6B). 
Further, B. garinii infection in WT mice induced up-regulation of biglycan 
mRNA expression in the aorta and spleen compared to the uninfected WT mice 
(Study II, Supplementary Figure 1). In addition, the expression of multiple cytokines 
in the B. burgdorferi ss, B. garinii, and B. afzelii infected KO and WT mice showed 
no difference between the mouse genotypes (Study II, Supplementary Figure 2). 
5.3 LB seroprevalence in Finland 50 years ago 
(Study III) 
5.3.1 The good-quality sera after 50 years 
To check the quality of the 50-year-old serum samples, we evaluated the presence of 
antibodies by measuring the VZV IgG antibodies in a random subset of 41 sera 
(Figure 13). Indeed, 38 of 41 serum samples contained detectable levels of VZV IgG 
antibodies corresponding to the expected VZV seroprevalence. Further, to check the 
immunoassay performance, 50 serum samples determined negative by the Borrelia 
WCS screening test were tested with recomBead IgG 2.0. All samples remained clear 
negative (data not shown). Thus, we assessed that the historical serum samples were 
of good-quality after long-term storage. 
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Figure 13. IgG antibody levels towards varicella zoster virus in a subset of 41 historical serum 
samples as measured by enzyme immunoassay. 
5.3.2 LB seroprevalence and the associated risk factors 
We analyzed 994 serum samples of the FMC survey for antibodies towards Borrelia 
(Figure 14). The serum samples were collected from 546 men and 448 women aged 
15 to 86 years from 24 locations in different parts of Finland during the years 1968 
to 1972.  
In total 199 of 994 (20.0%) sera were tested as Borrelia IgG positive. Hence, the 
unweighted LB seroprevalence among the healthy general population was 20.0% 
(95% Confidence Intervals (CI): 17.6–22.6). The association of gender, age, field of 
work, employment status, sport/exercise activities and regions of Finland with LB 
seroprevalence was analyzed (Study III, Table 1). The LB seroprevalence was 
slightly higher among males than females (21.8% vs 17.9%). The age of 50 years 
and older, unemployment, and regions of South and Central Finland were 
statistically significantly associated with LB seroprevalence (Study III, Table 1). 
However, the effect of migration of the study participants was not analyzed. 
Interestingly, the LB seroprevalence was about 20% in persons working in the 
field of agriculture and forestry, industry and mining, transportation and logistics, 
and service as well as among housewives and pensioners without statistical 
significance between the occupational groups (Study III, Table 1). Further, the self-
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reported perception of not feeling healthy, previous heart failure, and current heart 
valvular disease were statistically significantly associated with Borrelia 
seropositivity (Study III, Supplementary Table 1). 
 
Figure 14.  The locations of the collected serum samples of the Finnish Mobile Clinic Study during 
1968–72 analyzed for antibodies towards Borrelia. The number on the pie chart indicate 
the total number of sera collected at a certain location. The blue and red colours indicate 
the percentages of the serum samples negative or positive for Borrelia antibodies. 
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6 Discussion 
6.1 The role of BmpD in the purine nucleoside 
salvage in Borrelia 
Previous studies have suggested that the chromosomal encoded BmpA-D are 
important proteins for Borrelia survival and host infection (Ramamoorthy et al., 
1996; Bryksin et al., 2005; Pal et al., 2008). However, the localization and function 
of the Bmps have not been completely characterized. In Study I, the function of one 
representative Bmp protein, BmpD, was characterized and its potential as a vaccine 
antigen evaluated. 
The BmpA-D are lipoproteins with a typical signal sequence of about twenty 
amino acids from a methionine to a cysteine residue (Zückert, 2014; Åstrand et al., 
2019). The signal sequence is cleaved by the signal peptidase II (Zückert, 2014). 
Lipids, such as N-palmitoyl or S-diacylglycerol, are covalently attached to the sulfur 
atom of the cysteine. The lipid modification destinies the export of the protein to the 
exterior of the cytoplasm, either to the inner membrane or to the outer membrane of 
Borrelia. BmpA (also known as P39) was shown to be expressed on the outer surface 
(Bryksin et al., 2010). In contrast, BmpB, C, and D were found to be periplasmic 
proteins tethered to the inner membrane (Dowdell et al., 2017). In accordance, the 
results of the proteinase K-assay in Study I strongly suggests that BmpD is, indeed, 
a periplasmic protein. 
Despite the periplasmic localization of BmpD, LB patients had antibodies 
recognizing BmpD in Study I which is in line with earlier result by Bryksin and col-
leagues (Bryksin et al., 2005). However, the anti-BmpD antibodies did not prevent 
Borrelia infection since all BmpD immunized mice became infected in Study I. 
Accordingly, the antibodies against BmpA and BmpB did not protect mice from 
Borrelia infection (Gilmore et al., 1996; Pal et al., 2008). On the other hand, mice 
immunized with outer surface proteins, such as OspA and OspC, were protected 
from Borrelia infection (de Silva et al., 1996; Gilmore et al., 1996).  
Evidently, the host immune system can produce antibodies against proteins 
located both on the outer surface and in the periplasmic space of Borrelia. The 
proteins expressed on the outer surface of Borrelia are rapidly detected by host innate 
immune cells due to easy accession, leading to phagocytosis of Borrelia. After 
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phagocytosis, also the intracellular and periplasmic proteins are exposed, and can be 
presented to B cells for antibody production. However, Modolell and colleagues 
showed that antibodies against the periplasmic flagella did not contribute to Borrelia 
clearance (Modolell et al., 1994). In contrast, antibodies against outer surface 
proteins, OspA and OspB, were important for Borrelia clearance as anti-OspA and 
anti-OspB opsonized the spirochetes enhancing the phagocytosis of Borrelia 
(Modolell et al., 1994). The antibodies against periplasmic proteins, such as BmpD 
and flagella, do not detect their intracellular target antigen in intact Borrelia. Thus, 
no opsonization of Borrelia occurs which is one explanation why BmpD 
immunization did not protect mice from Borrelia infection.  
Yet, the LB vaccine development has clearly shown that the Borrelia protein 
localization is only one of multiple factors determing the efficacy of a vaccine 
antigen.  For example, the first human LB vaccine antigen, OspA, prevented Borrelia 
infection only in 80% of the study participants (Steere et al., 1998). 
After solving the crystal structure of BmpD, we characterized the first purine 
nucleoside-binding protein in Borrelia. Previously, BmpD has been described as a 
laminin-binding protein (Verma et al., 2009), as an endothelium-adhering protein 
(Antonara et al., 2007), and as a sugar transporter (Gherardini et al., 2010).  
However, the periplasmic localization combined with the results from the crystal 
structure presented in Study I revealed the function of BmpD as a substrate-binding 
protein of an ABC transporter for purine nucleosides. The substrate-binding proteins 
are important components of the ABC transporter complex as they bind to specific 
nutrients essential for the bacterial survival (Maqbool et al., 2015). Other known 
Borrelia substrate-binding proteins of an ABC transporter complex are the 
riboflavin-, phosphate-, and oligopeptide-binding proteins (Deka et al., 2013; 
Brautigam et al., 2014; Groshong et al., 2017). Recent in silico modelling results 
predicted the function of BmpA-D as purine nucleoside-binding proteins (Åstrand et 
al., 2019), which we now confirmed by solving the crystal structure of BmpD.  
Further, we showed that BmpD binds at least to two different purine nucleosides, 
adenosine and its derivative inosine as analyzed by LC-MS and MST. Both purine 
nucleosides are essential for Borrelia to scavenge from the host environment as 
Borrelia lacks the enzymes for de novo purine nucleoside biosynthesis (Fraser et al., 
1997; Pettersson et al., 2007). In the Borrelia cytoplasm, the BmpD-imported inosine 
can directly be converted to IMP, which is further converted to GMP, GDP, and GTP 
for RNA incorporation. The enzymes, adenylosuccinate synthase and lyase 
catalyzing the formation of IMP to AMP, are lacking in Borrelia (Pettersson et al., 
2007). Yet, the missing enzymes can be compensated by the uptake of adenosine via 
BmpD leading to the direct formation of AMP, ADP, and ATP for RNA 
incorporation.  
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As the yield of the ligand-free rBmpD was low due to the heavy three-step 
purification protocol, we chose the label-free MST approach for the ligand-binding 
assays. Possibly, further purine nucleosides could have been identified with other 
biomolecular binding assays, such as isothermal calorimetry (ITC) and surface 
plasmon resonance (SPR). The MST requires protein sample in the nanomolar range, 
whereas ITC and SPR consume large amount of highly concentrated sample. The 
binding affinities of T. pallidum PnrA to various nucleosides was studied by ITC 
(Deka et al., 2006). The methodological differences might explain why PnrA bound 
to adenosine (dissociation constant (KD)=0.3 µM), inosine (KD=0.2 µM), and 
guanosine (KD=0.07 µM) with 50 to 200-fold higher affinity than BmpD bound to 
inosine (KD=15 µM; SD 1µM). Different batches of purified LF-rBmpD were used 
in the label-free MST assay. Thus, some of batches probably contained residual 
bound adenosine even after the denaturation process which might explain why the 
KD of adenosine could not be calculated. For KD calculation, at least three 
reproducible binding curves should have been obtained by label-free MST assay. In 
addition, the label-free MST was not suitable to detect binding of BmpD to 
guanosine as guanosine emits autofluorescence. 
Interestingly, the binding of T. pallidum PnrA to pyrimidines was also measured 
(Deka et al., 2006). However, the binding affinities of pyrimidines (KD=6–13 µM) 
were considerably lower than the binding affinities of purines which were explained 
by structural differences. The pyrimidines have a base moiety of only one 
nitrogenous ring whereas purines have two (Figure 3). The two-ring base moiety of 
the purine nucleosides is sandwiched between two phenylalanines of PnrA forming 
hydrogen bonds with the aspartic acid residues, while the pyrimidine one ring moiety 
is smaller and cannot form similar hydrogen bonds. Further, the methyl group of 
thymidine hinders sterically the binding to glycine residue. Hence, T. pallidum PnrA 
was determined to transport purine nucleosides and not pyrimidines (Deka et al., 
2006). The ligand bound to BmpD was similarly stacked between the two 
phenylalanines and formed similarly hydrogen bonds with aspartic acid residues and 
glycine (close-up in Figure 11) as the purine nucleosides bound to PnrA. One can 
therefore suggest that BmpD also prefers purine nucleosides over pyrimidine 
nucleosides. 
In summary, the function of BmpD was identified as a periplasmic substrate-
binding protein of an ABC transporter for purine nucleosides. However, in vitro and 
in vivo studies with bmpD knock-out and complemented Borrelia strains would 
reveal the role of BmpD as a purine nucleoside-binding protein for survival and 
infectivity of Borrelia in the host. Further, the functions of BmpA, B, and C need to 
be investigated in more detail. For example, BmpA might present multifunctional 
roles as a laminin-binding and a purine nucleoside-binding protein (Verma et al., 
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2009; Caine & Coburn, 2016; Åstrand et al., 2019). These studies remain to be 
conducted in the future. 
6.2 The role of host molecule biglycan in Borrelia 
dissemination 
The virulence and infectivity of Borrelia is dependent on the dissemination and 
ability to persist in the host. The structure of host tissues contains multiple adhesion 
targets which Borrelia exploits for the purpose of dissemination and persistence. 
Biglycan is one proteoglycan expressed in the ECM of multiple tissue types and on 
the endothelium lining the blood vessels (Bianco et al., 1990; Salo et al., 2016). 
Recent in vitro studies showed that the DbpA and B adhesins of Borrelia bound to 
biglycan with different affinities depending on the genospecies (Salo et al., 2016). 
Therefore, we studied the infection of same three Borrelia genospecies in biglycan 
KO mice. Originally, the biglycan deficient mice were generated as animal disease 
model for osteoporosis studies (Xu et al., 1998). Hence, we needed to generate a 
novel biglycan KO mouse model which was susceptible for Borrelia infection. The 
results of Study II revealed that the three Borrelia genospecies behaved differently 
in the biglycan KO mice. 
The in vitro assays showed that B. burgdorferi ss and B. garinii adhered strongly 
to biglycan expressed on endothelial cells (Salo et al., 2016) suggesting that 
dissemination of these two Borrelia genospecies could be impaired in biglycan KO 
mice. However, the infectivity of B. burgdorferi ss and B. garinii was not affected 
by the lack of biglycan. The biglycan deficient and wildtype mice became equally 
infected as evidenced by detection of Borrelia in tissues and significant antibody 
response towards Borrelia in both mouse genotypes. Similarly, the B. burgdorferi ss 
was able to infect and disseminate in mice deficient of decorin, a close relative of 
biglycan (Brown et al., 2001). Borrelia expresses a plethora of adhesion proteins 
with overlapping adhesion targets in the host tissues (Caine & Coburn, 2016). One 
missing adhesion molecule can be compensated with multiple other adhesion targets. 
Thus, the results imply that Borrelia-biglycan interaction is not necessary for B. 
burgdorferi ss and B. garinii. 
In contrary, the in vitro results suggested that biglycan is not an adhesion target 
in the host tissues for B. afzelii as the DbpA and B adhesins of B. afzelii did not bind 
to biglycan (Salo et al., 2016). Unexpectedly, B. afzelii was unable to establish 
infection in the biglycan deficient mice. The non-infectivity of B. afzelii might be 
explained by the poor binding to biglycan and decorin host molecules, while B. 
burgdorferi ss and B. garinii bound strongly or moderately to biglycan and decorin 
(Salo et al., 2011; Salo et al., 2016). Possibly, B. afzelii needs both adhesion 
molecules DbpA and DbpB as well as both adhesion targets in the host to establish 
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infection. On the other hand, B. afzelii might express uncharacterized adhesion 
proteins essential for mediating binding to biglycan, which have yet to be identified. 
Further, B. afzelii presented low virulence in the wildtype mice suggesting that the 
needle-inoculated load of bacteria (105) was too low. The B. afzelii A91 strain was 
isolated from skin biopsy samples of Finnish LB patients (Panelius et al., 2001). In 
Study II, this strain was used for first time in mouse infection studies. Probably, with 
higher inoculation load, the B. afzelii A91 strain would have presented higher 
virulence in the wildtype mice. Generally, B. afzelii displays high virulence in 
mammalians as it is the most common genospecies causing LB in Finland (Carlsson 
et al., 2003). 
In addition to the structural role of biglycan, the proteoglycan promotes the host 
inflammatory reactions in sterile inflammation caused by tissue stress, injury or cell 
death, which are common features in myocardial infarctions, atherosclerosis, 
autoimmune diseases, and cancer (Schaefer, 2014; Frevert et al., 2018). However, 
biglycan affects also the host inflammatory reaction against bacterial infections. In 
Study II, B. burgdorferi ss infected biglycan deficient mice had persisting joint 
inflammation and higher number of spirochetes in the joints compared to the 
wildtype mice. In contrast to B. burgdorferi ss, the joint inflammations in the 
biglycan deficient mice caused by B. garinii were moderate.  
The variation in the intensity of the joint inflammation might be accounted by 
the different genospecies as B. burgdorferi ss presents greater inflammatory potential 
than B. garinii and B. afzelii (Strle et al., 2009; Cerar et al., 2016). B. burgdorferi ss 
induced significantly higher levels of chemokines and cytokines than B. garinii and 
B. afzelii in stimulated macrophages of healthy donors (Strle et al., 2009). Further, 
patients infected with B. burgdorferi ss experienced a more severe form of LB 
associated with following symptoms, such as fever, neck stiffness, malaise, and 
fatigue, than patients infected with B. garinii and B. afzelii (Cerar et al., 2016). 
On the other hand, similarly to Study II, B. burgdorferi ss infected mice deficient 
in other proinflammatory molecules, 5-lipoxygenase, MyD88, and TLR2, had more 
severe and persistent arthritis including high levels of spirochetemia in tissues 
despite normal antibody production (Wooten et al., 2002; Bolz et al., 2004; Blaho et 
al., 2011). 
Biglycan, 5-lipoxygenase, MyD88, and TLR2 are not only involved in the host 
proinflammatory reaction to clear the invading bacteria, but are also involded in the 
rapid resolution of the inflammatory reaction (Basil & Levy, 2016). Without the 
initial proinflammatory reaction induced by the aforementioned molecules, there is 
also no host induced resolution of the host inflammatory reaction. Thus, the host 
inflammatory reaction continues in the bacterial infection sites as manifested by the 
long-term arthritis reaction in the B. burgdorferi ss infected mice deficient of the 
proinflammatory molecules production (Wooten et al., 2002; Bolz et al., 2004; Blaho 
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et al., 2011). The proinflammatory effects of biglycan in other bacterial infection 
have been under investigation. For example, the presence of biglycan enhanced the 
complement-mediated killing of the respiratory pathogen Moraxella catarrhalis 
(Laabei et al., 2018). 
In summary, Study II revealed that the host molecule biglycan has a dual role in 
Borrelia infection. On one hand, biglycan alters the infectivity and dissemination of 
Borrelia depending on the genospecies. On the other hand, biglycan affects also the 
host proinflammatory reaction. 
6.3 LB seroprevalence in Finland 50 years ago 
Virtually all LB patients develop Borrelia-specific IgG antibodies (Dessau et al., 
2018). The antibodies towards Borrelia persist for decades after the initial infection 
(Kalish et al., 2001), and thus, are useful for seroprevalence studies. 
The first LB seroprevalence studies using human serum samples were conducted 
in the late 1980s and in the beginning of 1990s (Smith et al., 1988; Gustafson et al., 
1990). However, no LB seroprevalence studies had been conducted during the 
decades before the description of the LB disease entity in the late 1970s and early 
1980s (Steere et al., 1977b; Burgdorfer et al., 1982). Study III is the first study 
shedding light on the exposure to LB infection in a European population half a 
century ago. The analyzed human serum samples were a subset of samples collected 
during the Finnish Mobile Clinic study in the years 1968–72.  
Besides Study III, there is one another LB seroprevalence study using historical 
serum samples of American gray wolves in the years 1972–98 (Thieking et al., 
1992), the same time period as the FMC study was conducted. Borrelia antibodies 
were detected in 3% of the historical wolf serum samples (Thieking et al., 1992). 
The presence of Borrelia antibodies in the historical wolf serum samples, and the 
historical case reports of patients with skin or neurological conditions after a tick 
bite (Afzelius, 1910; Garin & Bujadoux, 1922) led to the assumption that infections 
caused by Borrelia were not uncommon in Europe and North America in the late 
19th and early 20th centuries. At that time, the European, especially the Northern 
European, economies were still heavily depending on agriculture and forestry which 
further supports the expectation of Borrelia seropositive people in the 1970s. Even 
today, the farmers and forestry workers are high-risk occupational groups for LB 
(Dessau et al., 2018). 
The overall LB seroprevalence in Finland in 1968–72 was 20.0% which was five 
times higher than the recent seroprevalence of 3.9% observed in serum samples 
collected in 2011 (van Beek et al., 2018). Generally, comparisons between two 
epidemiological studies need to be considered carefully as there is no “gold 
standard” for serological methods to detect Borrelia antibodies. However, in this 
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case, both Finnish seroprevalence studies were conducted with the same serological 
test algorithm. Hence, the comparison is reasonable. The five times higher 
seroprevalence could be partly explained by the agrarian society 50 ago compared 
to the service-based society of Finland in the 21st century.  
Yet, the considerably high LB seroprevalence was surprisingly not associated 
with the occupation of the study subjects (Study III, Table 1). High LB 
seroprevelance was distributed evenly among those working in agriculture and 
forestry, industry and mining, transportation and logistics, and in service. Further, 
unemployment and age of 50 and older were risk factors associated with LB 
seroprevalence. The unemployed included housewives, school children and students 
who possibly spent more time gardening, berry picking and doing sport activities, 
which could have led to more frequent encounters with ticks. The aforementioned 
explanation could also be applied to the increased risk of LB in study subjects with 
older age. Finally, the regions of Central and South Finland were significantly 
associated with LB seroprevalence in 1970s, whereas today, Southwest Finland is a 
region with probably the highest tick density (Laaksonen et al., 2017; Laaksonen et 
al., 2018) and LB incidences (Sajanti et al., 2017). 
Another interesting finding in Study III was the analysis of the self-reported 
symptoms, diseases and perceptions of health of the study subjects after adjusting 
the statistical analyses for sex, age-groups, and regions (Study III, Supplementary 
table 1). Logically, the LB seropositive study participants reported more frequently 
of not feeling healthy compared to the LB seronegative persons suggesting that, 
indeed, the study subjects suffered from unspecified symptoms affecting their well-
being. Surprisingly, the difference was even statistically significant. In contrast, the 
self-reported diseases, previous heart failure and current heart valvular disease, were 
also statistically significantly associated with LB seropositivity, but clinically these 
conditions are not associated with LB (Steere et al., 2016).  
In summary, the results of Study III revealed the considerably high LB sero-
prevalence in Finland 50 years ago. The historical seroprevalence is important for 
understanding that today the LB risk is relatively low. Also, the historical 
seroprevalence strongly suggests that the hysteria around ticks and tick-borne 
diseases created by (social) media is overrated. On the other hand, the knowledge on 
ticks and tick-borne diseases by medical professionals and citizens, diagnostics and 
efficient treatments with antibiotics have probably led to the low LB seroprevalence 
today. 
6.4 Strengths and weaknesses of the study 
In Study I, we evaluated the role of BmpD in Borrelia from the perspective of 
infection biology and structural biology. Often, studies on bacterial proteins are 
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conducted either from the infection biological (Brooks et al., 2006; Kung et al., 
2016), or from the structural biological perspective (Deka et al., 2006; Brautigam et 
al., 2014). However, in Study I, we combined data from both perspectives. On one 
hand, we analyzed the structure and function of BmpD as a purine nucleoside-
binding protein by solving the crystal structure of BmpD, LC-MS, and ligand-
binding assays. On the other hand, we studied the cellular localization of BmpD in 
Borrelia. Importantly, with the mouse immunization study, we also analyzed 
whether BmpD would be a novel LB vaccine candidate. 
Yet, from the infection biological perspective, there are limitations. Borrelia 
strains lacking bmpD and complemented with bmpD should have been generated to 
evaluate the role of BmpD in the survival of Borrelia in vitro. Further, assays to 
determine the purine nucleoside transportation could have been assessed with these 
strains. Moreover, mouse infection studies with these Borrelia strains would have 
revealed the effect of BmpD on the infectivity and dissemination of Borrelia in the 
host. 
In Study II, we generated a novel mouse model which lacked biglycan and was 
susceptible for Borrelia infection. There are multiple mouse models deficient of 
different proteoglycans, such as biglycan, decorin, fibromodulin, and lumican, which 
are all expressed in the ECM of connective tissues (Ameye & Young, 2002). 
Borrelia infection has been only studied in the decorin deficient mouse model 
(Brown et al., 2001), although Borrelia adheres to multiple ECM targets (Caine & 
Coburn, 2016). Thus, Study II, is the second study to analyze the effect of a 
proteoglycan on Borrelia infection. Here, we analyzed the effect of biglycan on the 
infection and dissemination of three different Borrelia genospecies which represent 
the three most common human pathogens. We showed that biglycan affects the 
course of infection depending on the Borrelia genospecies, but we also showed that 
biglycan affected the host proinflammatory reaction. 
Furthermore, usually, Borrelia infection studies are only assessed with B. 
burgdorferi ss, the common human pathogen in the USA. In contrast, in Study II, we 
used three different genospecies. Hence, the study results are applicable to Europe 
and Asia, where B. afzelii and B. garinii are common pathogens. However, repetition 
of the mouse infection study with B. afzelii could have been conducted. Thus, we 
could have determined whether the particular strain, B. afzelii A91, is truly non-
infectious or only dissemination-defective in the biglycan KO mice.  
Study III is a unique study set-up as a 50-year-old collection of serum samples 
of Finnish healthy population was available for serological studies. National health 
surveys have been conducted regularly in Finland since the first survey, FMC, in 
1968 to 1972. The serum sample collection of the FMC is probably one of the oldest 
and largest collection worldwide, which is available for scholars. Importantly, for 
every serum sample, we could link the corresponding data about the background, 
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such as age, sex, region, occupation, outdoor activities, and answers of health 
questionnaire, such as symptoms, previous and current diseases, from the study 
participants. However, the effect of migration was not assessed. Although, we could 
show that the highest seroprevalence rates were in South and Central Finland, but 
we do not know if the same regions are also the locations of the acquired Borrelia-
infected ticks.  
Moreover, the three-step serological test algorithm used in Study III was the 
same as in the previous study (van Beek et al., 2018). Hence, the comparison of the 
seroprevalence rates 20% in 1968–72 vs 3.9% in 2011 was possible. Yet, we cannot 
analyse the exact time of first Borrelia infection and whether recurrent Borrelia 
infections had occurred as the Borrelia IgG antibodies remain elevated for decades. 
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7 Conclusions 
The Borrelia spirochetes transmitted by ticks to humans are causing the infectious 
disease Lyme borreliosis, which was discovered only 40 years ago. Since then, the 
research on Borrelia cell biology, pathogenesis, and diagnostics has been ongoing. 
Still today, the function of the majority of Borrelia proteins has not been thoroughly 
characterized.  
Study I revealed the structure and function of one protein of Borrelia, Basic 
membrane protein D, as a substrate-binding protein for purine nucleosides involved 
in the purine salvage pathway of Borrelia. Further, the role of the host molecule 
biglycan in Borrelia pathogenesis was characterized in Study II. Importantly, the 
determination of structure and function of bacterial proteins and of host binding 
molecules are the basic requirements to discover new bactericidal therapies. Novel 
drug molecules targeting BmpD could interfere with the metabolism of Borrelia. 
Hence, the DNA and RNA synthesis in Borrelia would be disrupted, which would, 
in turn, lead to killing of the bacteria. Also, drug molecules mimicking the structure 
of biglycan could result in anti-adhesion based treatment. 
The historical LB seroprevalence study brought to light that LB has been a 
common infectious disease in Finland 50 years ago. Further, the observed high 
seroprevalence is a scientific argument to proportionate the current scare on ticks 
and tick-borne diseases.  
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